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1. Introduction  
 Cancer is one of the leading causes of death worldwide. According to WHO, 8.8 
million people died in various forms of malignant cancer in 2015. Almost half of the 
cancer deaths are from lung (1.69 million), liver (788 thousand), colorectal (774 
thousand), stomach (754 thousand) and breast (571 thousand) cancers. Based on the 
factsheet of EUCAN, the most frequently diagnosed type in european countries is breast 
cancer, followed by colon and lung cancer for women (accounting for 48.8 % in total), 
and prostate cancer, followed by lung and colon cancer for men (accounting for 51.4 % 
in total) [1]. For females, breast cancer shows the highest death rate, while for males, lung 
cancer kills the most patients [2]. The mortality rate for all cancers varies from country 
to country, as a factor of economic level and local health care system. In Europe, based 
on the data collected from 2011-2013, the highest mortality rate (male and female 
together) was in Hungary, followed by other central european countries (Figure 1, 
Appendix 1) [3]. 
 
Figure 1. Mortality rate of all cancers per 100 thousand inhabitants in 2013. The highest rate was 
in Hungary (352.1), and the lowest rate was reported in Turkey (186.4) [3]. 
Cancer treatment depends on the type and the stage of the malignancy. In most cases 
surgical resection is needed, which is later combined by chemotherapy or radiation 
therapy. Another example is neoadjuvant therapy, when the usage of chemotherapeutics 
 
186.4 – 236.8 
236.9 – 249.6 
249.7 – 269.7 
269.8 – 291.1 
291.2 – 352.1 




precedes surgery in order to shrink the tumor [4] [5] [6]. Besides conventional therapies, 
targeted therapies and immunotherapies are emerging treatment possibilities. 
In the last decades, survival rates have improved, especially for breast and prostate 
cancers, or melanoma (Figure 2). Better outcome is due to improvements in all treatment 
fields. In surgery, novel techniques such as keyhole surgery or lumpectomy allow more 
precise interventions, and further development is expected by the introduction of the 
iKnife [7]. Radiotherapy is performed with more focused devices, new drugs were 
introduced in chemotherapy regimens, and the growing field of biological therapy 
provides novel, cancer specific approaches (e.g. rituximab for non-Hodgin lymphoma [8], 
trastuzumab for HER-2 positive breast cancer [9], or combined immunotherapeutic 
strategies for melanoma using interferon-α, interleukin-2 and immune checkpoint 
inhibitors [10]). However, there are some malignancies, where only minor improvements 
were observed. Tumors, such as lung or pancreatic cancers continue to show poor 
outcome (Figure 2). 
 
Figure 2. Ten year relative survival (%) of selected cancers for adults in England and Wales. 




Treatment failure is often due to the inherent or acquired resistance of the tumors, 
mediated by the tumor microenviroment (the stroma), or molecular changes, that can 
occur even in response to treatment, as tumor cells can adapt to various toxic impacts. 
1.1. Hallmarks of cancer and therapy resistance 
Cancer is a group of diseases consisting of over 100 different conditions. The primary 
distinction of cancers is based on the tissue of origin (e.g. lung cancer, breast cancer) and 
the cell type (e.g. carcinomas, sarcomas, adenocarcinomas) [12]. Despite the complexity 
of the many types of cancers, Hanahan and Weinberg defined the following 6 hallmarks 
that characterize all cancer types: (1) acquiring autonomous growth signals, (2) evasion 
of growth inhibitory signals, (3) evasion of apoptotic cell death, (4) unlimited replicative 
potential, (5) capability to form new blood vessels – angiogenesis – and (6) invasion and 
metastasis [13]. The original list of hallmarks were later completed with two enabling 
characteristics. Genome instability and tumor-promoting inflammation provide a 
permissive environment to acquire the above hallmarks. Reprogramming energy 
metabolism and avoiding immune destruction were defined as emerging hallmarks, as 
their importance in carcinogenesis is still under debate [14]. 
1.1.1. Role of mutations and plasticity of the tumor cells in drug resistance 
Although it is not considered as a hallmark, intrinsic or acquired anticancer therapy 
resistance is frequently observed in all cancer types. The phenomenon of drug resistance 
occurs when tumor cells become insensitive to treatment. The development of cancer 
drug resistance is linked to DNA mutations or other metabolic changes including 
epigenetic events due to the plasticity of cancer cells, since these alterations serve as 
sources of new phenotypes during tumor progression [15] [16]. The new phenotypes 
emerge as a consequence of the multiple environmental pressures that compel the 
malignant cells to continuously change and adapt. In agreement with the Darwinian 
evolution model, cells, which obtained genetic mutations (or epigenetic changes) that 
result in growth advantage become predominant compared to neighboring cells. Clones 
with higher proliferation rate then expand within the tumor. Successive advantageous 
mutations/alterations lead to waves of clonal expansion, resulting in tumor heterogeneity 
[17] [18]. 




mainly proto-oncogenes, tumor supressor genes and DNA repair genes, sometimes called 
“drivers” of cancer [12]. According to the Cancer Genome Atlas Pan-Cancer effort, where 
mutation patterns of 3281 tumors from 12 cancer types were thoroughly analyzed, 2 to 6 
such driver mutations are sufficient for oncogenesis [19]. The analysis also identified 
oncogenic mutations that can occur in any type of cancer, such as the mutations of histone 
modifiers, but reported several tissue specific genetic alterations as well, which affect 
mostly transcriptional factors and transcriptional regulators. Taken together, mutations 
and epigenetic plasticity of  the malignant cells create a heterogeneous tumor where 
subclones can have different DNA alterations ranging from point mutations to large 
chromosomal aberrations (e.g. chromosomal translocations) [20] [21] [22] [23] and 
abnormal DNA methylation pattern variations [24] [25]. Tumor heterogeneity has a 
profound clinical impact. Therapy acts as a selective pressure, and in response, the fittest 
– most resistant – subclones are selected to survive, which manifests in tumor relapse [26] 
[27]. 
As an example, 5-fluorouracil (5-FU) resistance of colorectal cancer appears with the 
recurrence of the tumor that was initially responding well to this chemotherapeutic agent. 
When mRNAs were extracted from the tumor that already became resistant to 5-FU 
treatment, high levels of dihydropyrimidine dehydrogenase (DPD) transcripts were 
found. DPD is responsible for the inactivation of 5-FU before it is converted to its active 
form (to fluorodeoxyuridine by thymidine phosphorylase) [28]. Moreover, amplification 
of the TYMS locus (thymidylate synthetase, target of the activated 5-FU) was correlated 
with poorer survival among patients with advanced, metastatic colorectal cancer, who 
were treated with 5-FU previously [29] [30] [31]. 
Resistance derived from tumor heterogeneity is more pronounced when targeted drugs 
are used, due to the highly specific targeting of certain malignant alterations. As an 
example, when patients with chronic myelogenous leukemia (CML) are treated with 
imatinib, kinase-domain mutations commonly emerge, leading to clinical drug resistance 
and relapse [32]. A study proved that these mutations can already be present in a tumor 
subpopulation at the time of diagnosis, before imatinib treatment is initiated [33]. Another 
example is when patients with colorectal cancer are treated with cetuximab and 
irinotecan, a subpopulation with p.K57T missense mutation in the MAP2K1 gene will 




1.1.2. Mechanisms of drug resistance and multidrug resistance (MDR) 
The most common mechanisms that confer drug resistance to tumor cells are the (a) 
increased metabolic degradation of drugs, (b) keeping molecular targets at a low level, 
(c) increased DNA damage repair, (d) changed apoptotic pathways, (e) mutation in the 
target protein, (f) trapping drugs into acidic compartments, (g) alterations in the cell cycle 
and checkpoints and (h) the increased efflux by energy dependent transporters [15] [35]. 
Besides the above conventional mechanisms, cells can ‘escape’ from the treatment by 
epithelial-mesenchymal transition (EMT) [15], and certain micro-RNAs seem to 
contribute to the emergence of drug resistance as well [36]. 
Certain mechanisms from the above list can confer resistance to a single agent (the agent 
with which the treatment was conducted), while other forms provide cross-resistance to 
additional drugs. If cross-resistance is efficient against structurally unrelated and 
functionally distinct drugs, the phenotype is termed “multidrug resistance” (MDR) [37]. 
Overexpression of the ATP-binding cassette efflux transporters (ABC-transporters) in the 
plasma membrane of the malignant cells is one of the most common and effective 
mechanisms of MDR. The main ABC-transporters related to multidrug resistance are 
ABCB1 (P-glycoprotein, P-gp) [38], ABCG2 (BCRP) [39] [40] [41] and ABCC1 (MRP1) 
[42]. These transporters have broad substrate specificity, they can recognize and extrude 
a wide range of xenobiotics from the (tumor) cells, keeping low intracellular drug 
concentrations. Many anticancer therapeutics, either conventional (e.g. vinca-alkaloids) 
or targeted drugs (e.g. EGFR inhibitors) that are currently in use are subjects of transport 
by the ABC pumps [37]. The substrate specificity of the 3 main MDR ABC-transporters 
are partly overlapping, nevertheless when cultured cancer cells are treated with 
chemotherapeutics, the major mechanism of multidrug resistance is mediated by P-
glycoprotein [35]. In addition, when mice bearing Brca1- and p53-deficient mammary 
tumors were treated with doxorubicin (a P-gp substrate), resistance frequently occurred 
and was linked to the overexpression of the P-gp ortholog Mdr1a and/or Mdr1b [43] [44]. 
P-gp  is widely expressed also in many human cancers, including cancers of the 
gastrointestinal tract (small and large intestine, liver cancer, and pancreatic cancer), 
cancers of the hematopoietic system (myeloma, lymphoma, leukemia), cancers of the 
genitourinary system (kidney, ovary, testicle), and childhood cancers (neuroblastoma, 




solid cancers, the contribution of P-gp to poor chemotherapy response was demonstrated 
[37]. P-gp mediated (and in general ABC-transporter mediated ) MDR is still a serious 
obstacle in cancer therapy, as during treatment, if the fittest clones, which arise due to the 
selective pressures are overexpressing P-gp, the tumor will most probably stop 
responding to P-gp substrate chemotherapeutics. 
1.1.3. Physiological role and function of ABCB1 
ABC-transporters are transmembrane proteins controlling the passage of their substrates 
across biological membranes and barriers under normal physiological conditions. Thus, 
ABC-pumps play a crucial role in the distribution of their endogenous substrates 
(reviewed in [37]). Moreover, ABC transporters make up a complex cellular defense 
system responsible for the recognition and removal of environmental toxic agents [46]. 
Accordingly, ABCB1 [47] and ABCG2 [48] [49] proteins are expressed e.g. in the blood-
brain barrier, where they protect the brain from xenobiotics. P-gp is expressed also in the 
liver, intestine and kidney [45] [50]. 
P-glycoprotein is a 170,000-dalton molecular weight phosphoglycoprotein comprised of 
two transmembrane domains (TMD), each containing six transmembrane helices, and two 
nucleotide binding domains (NBD) [51]. Extrusion of xenobiotics by P-gp from the cell 
is an energy-dependent action fueled by ATP hydrolysis [52].  
Figure 3. Structure of P-gp, based on molecular dynamics simulation [54]. Green: lipid bilayer, 




P-gp in its drug recognition (inward facing) state allows drug binding and asymmetric 
occlusion of an ATP in each NBD domains. Upon drug and ATP binding, the subsequent 
hydrolysis of the two ATPs triggers a conformational motion, when the transition of the 
inward facing state to the outward facing state takes place, resulting in the release of the 
captured drug into the extracellular space via the pore that is formed by the TMD helices. 
After drug release, P-gp returns to the inward facing state, and P-gp can start the 
conformational cycle again [53]. Inward-facing and outward facing states are shown in 
Figure 3. 
1.2. Overcoming MDR by inhibition or evasion of P-gp 
In vitro experiments of malignant cells showed that the relative amount of surface P-gp 
strongly correlates with the degree of drug resistance, and if P-gp is inhibited, MDR 
cancer cells regain their original sensitivity to the drugs that are subjected to transport 
[55] [37]. Considering that Mdr1a/b KO mice are viable and fertile [47], it was a 
reasonable strategy to inhibit the function of P-gp in vivo, and co-administer 
chemotherapeutics with the inhibitor to reverse MDR in tumor cells [56]. Unfortunately, 
the in vitro effectiveness of inhibitors has not translated to the clinic. Clinical trials were 
conducted with 3 generations of P-gp inhibitors (e.g. the first generation inhibitors 
cyclosporin or verapamil, PSC833 from the second generation, or tariquidar as a third 
generation inhibitor), but no remarkable benefit was reported, and the reasons for failure 
were assosiated to side effects, undesirable pharmacokinetic interactions or simply to 
ineffectiveness [37] [57]. Thus, novel approaches are needed to fight against MDR in 
cancer, which do not interfere with the role of P-gp in pharmacological barriers. 
Presently, drug candidates are commonly tested to determine if there is an interaction 
with ABC transporters. One strategy to improve therapy response and avoid transporter 
mediated MDR is to design new classes of anticancer agents that simply bypass the 
multidrug transporters [58]. This can be achieved by modifying already existing 
therapeutics in a way that they are no longer recognized by the transporters (e.g. design 
of daunomycin  [59] or camptothecin [60] analogues), or by discovering novel agents that 
lack MDR transporter interaction. Another advance is the encapsulation of drugs in 
nanoparticles or liposomes, preferably designed for targeted delivery [58]. Liposomal 
formulations of MDR substrate drugs have a greater potential against MDR cancer, e.g. 




delayed onset– as it was demonstrated by our research group – when the effect of 
doxorubicin and liposomal doxorubicin treatment was compared [61]. Moreover, both 
overall and relapse free survival were increased remarkably when the liposomal 
formulation was administered. In an earlier study, conducted by Krishna and Mayer [62], 
when liposomal doxorubicin and the second generation P-gp inhibitor PSC833 were co-
administered in P388 ascites tumor bearing mice, the tumor volume was reduced more 
efficiently compared to when the combination of PSC833 and free doxorubicin was used, 
albeit the tumor did not diminish completely. 
1.3. Exploiting the phenomenon of collateral sensitivity 
There is an alternative strategy against drug resistant cancer, which is substantially 
different from the efforts to overcome MDR by blocking transporter function, or to avoid 
drug extrusion by designing molecules which are not recognized by the ABC-pumps. The 
novel approach relies on the phenomenon called collateral sensitivity (CS), which was 
originally observed and described as an interesting anomaly by Szybalski and Bryson, 
who found compounds that provoked induced sensitivity to resistant bacteria strains [63]. 
They hypothesized that during isolation of strains possessing resistance to one 
antibacterial substance, associated characters producing higher sensitivity 
(hypersensitivity) to another agent might be selected. As a conclusion, they proposed to 
apply such compounds as selective agents alone, or in combination with other drugs to 
prevent the emergence of bacterial resistance. The hypothesis they claimed became well 
accepted, and the definition of collateral sensitivity was soon adapted for non-bacterial 
cases. CS was observed in insects (since 1950s, termed enhanced susceptibility [64] [65]), 
yeast [66] and protozoa [67] (both since the 1970s) or weeds (first report from 1987 [68]). 
In cancer, the first report of collateral sensitivity is from 1951 [69], when 6-
mercaptopurine resistant mouse leukemic cells were noticed to be more sensitive to 
methotrexate than the parental line. 
Collateral sensitivity is a type of synthetic lethality, which in MDR tumor cells is linked 
to the cellular alterations resulting from the adaptation to cytotoxic/cytostatic drugs, and 
associated with vulnerabilities that were created concurrently to drug selection [70]. 
Accordingly, collateral sensitivity of MDR tumor cells can be exploited therapeutically 




hallmarks of cancer) that might be targeted by new drugs. Theoretically, administration 
of collateral sensitivity provoking compounds have the potential to prevent MDR tumor 
formation by the preferential killing of MDR cells in a heterogeneous tumor population 
[71]. 
1.3.1. Experimental evaluation of collateral sensitivity of P-gp expressing MDR 
cancer cells 
Several compounds demonstrating preferential hypertoxicity to P-gp positive cell lines 
were listed in a recent review [70], proving that application of drugs eliciting collateral 
sensitivity can be effective also against MDR cancer cells with pathological P-gp 
overexpression. 
The compounds were identified in various in vitro cytotoxicity experiments, which served 
as the basis of determining their potency. A common way to evaluate the extent of 
collateral sensitivity is to calculate the ratio of cytotoxicity measured against the parental, 
P-gp negative cell line divided by the cytotoxicity measured against its multidrug 
resistant, P-gp positive derivative [71]. The cytotoxicity of a compound is expressed as 
the half-maximal inhibitory concentration (IC50) value, and their ratio is termed 
selectivity ratio (SR) [72]. If SR > 1, the compound is killing the MDR cells preferably 
over the parental line, while a SR < 1 indicates that the tested compound exerts greater 
toxicity towards the parental cell line, e.g. because  the test compound is a P-gp substrate. 
Correspondingly, higher SRs refer to more pronounced collateral sensitivity. However, 
selectivity ratio is not the only factor of a compound’s potency, the cytotoxicity (IC50) 
value is also relevant, as it can range from nanomolar to millimolar concentrations. 
Moreover, the P-gp expressing MDR cells can be targeted via non-transporter related and 
also by P-gp mediated mechanisms. Therefore the contribution of P-gp in CS has to be 
clarified.  As explained above, drug efflux by P-gp is a frequent form of MDR, thus P-gp 
mediated CS might be preferable over mechanisms related to cell line specific alterations 
evolved during drug selection of the cell line. There are 3 common ways to address the 
observed hypertoxicity of an MDR targeting drug candidate to P-gp. First, by testing the 
compound against additional parental and P-gp positive MDR cell line pairs, the 
robustness of selectivity can be investigated, and collateral sensitivity has to appear across 
all cell pairs, if P-gp is involved. Additionally, if a compound’s hypertoxicity towards P-




incubated in a non-toxic concentration, the observed CS is P-gp dependent (concurrently 
the cytotoxicity towards the parental cell line has to be unaffected). Abrogation of 
selectivity may be achieved also by siRNA driven P-gp knockdown [71], or by the use of 
a tetracycline controlled promoter, where the presence of the antibiotic suppresses the 
transcription of P-gp, and P-gp mediated CS of the MDR line is observed only when 
tetracycline is absent [73]. The third way is to apply MDR1-transfected cell lines, which 
are created from parental lines with MDR1 gene insertion. The MDR1 transfected resistant 
cell lines, in contrast to P-gp expressing MDR cell lines created with in vitro selection of 
parental lines in chemotherapeutics, lack other cellular changes that might have occurred 
during drug selection, thus cell line specificity of the experienced selective toxicity is 
minimal [71]. 
1.3.2. Examples of collateral sensitivity provoking agents from the literature 
P-gp expressing MDR cancer cells are indeed targetable [70] [72]. Most of the collateral 
sensitivity provoking substances (CS agents) were found serendipitously, when the 
original aim of the research teams was to investigate cross resistance, or simply the lack 
of transporter mediated resistance of anticancer substances. In several cases, the observed 
hypersensitivity of MDR cells could be linked to certain cellular changes that cells 
acquired during drug selection in parallel to P-gp overexpression. 
A good example for this kind of cell line specific hypertoxicity is the case of 2-deoxy-D-
glucose (2-DG), which was found to kill the vinblastine resistant and P-gp overexpressing 
cell line KB-V1 more effectively than its parental (KB-3-1 cervix carcinoma) form [74]. 
2-DG provoked collateral sensitivity in 2 other KB-3-1 derived MDR cell lines, the 
colchicine selected KB-C1 and doxorubicin selected KB-D1, but the extent of 
hypertoxicity was not proportional to the level of multidrug resistance. Selective toxicity 
of 2-DG was first associated to the decreased expression of GLUT-1 transporter found in 
MDR cells, but finally it was linked to altered apoptotic pathway of resistant lines. 
Another compound that originally was believed to be an MDR-selective agent is the 
natural product austocystin D [75]. A later study by Marks et al. has shown that 
austocystin D directly interacts with P-gp as a low affinity substrate, although this 
interaction is not responsible for its selective toxicity towards MDR cells [76]. As they 
explain, the observed hypertoxicity is linked to the elevated levels of the Cytochrome 




entering the cell. Thus, certain P-gp expressing MDR cells, thanks to the potential 
coordinated upregulation of CYP enzymes and ABC-transporters are more susceptible to 
austocystin D. 2-DG and austocystin D, albeit killed the investigated MDR cells 
preferably, are not ideal drug candidates, because their selective manner is tied to a special 
cellular change, which is not expected to represent resistant tumors in general. 
In contrast, there are other compounds that were published to selectively kill P-gp 
overexpressing cells, where the selective action was mediated by the transporter. The 
hypertoxicity of verapamil towards MDR cells was widely studied in Chinese hamster 
ovary (CHO) cells. MDR cells derived either from E29 or from AuxB1 parental CHO cell 
lines become sensitive to verapamil after selection in vincristine or colchicine, and 
sensitivity was linked to the overexpression of hamster P-gp [77] [78] [79]. By using the 
same AuxB1 and its colchicine resistant derivative (CHRC5) hamster cell lines, Laberge 
et al. proved the MDR-selective toxicity of verapamil, and discovered the MDR-selective 
toxicity of the electron transport chain (ETC) complex I inhibitor rotenone [80]. When 
verapamil and rotenone were tested in the presence of PSC833 (a 2nd generation P-gp 
inhibitor), the preferential toxicity against MDR cells was completely abrogated. Besides 
hamster cell lines, verapamil was also studied in a P-gp expressing human MDR cell line 
K562/ADR, but it showed only a slight, 1.78 fold selectivity compared to parental K562 
[81]. Two additional compounds, TritonX-100 [82] and reversin121 [83] were identified 
and published as MDR-selective agents against MDR CHO cells. While the hypertoxicity 
of TritonX-100 was demonstrated only against MDR hamster cell lines, and was found 
to be equally toxic to LR73 and the mouse mdr1a transfected LR73/1A CHO cell lines, 
reversin121 killed the human KB-V1 cell line preferably over KB-3-1. 
In search for novel anticancer compounds, Nakagawa-Goto et al. tested several unique 
flavonoids with desmosdumotin B skeleton, and reported a striking collateral sensitivity 
towards the human MDR cell line KB-VIN, which is a vincristine selected derivative of 
the parental KB nasopharyngeal carcinoma line [84]. The most potent compounds were 
6,8,8-triethyldesmosdumotin B and its 4’-Me and 4’-Et substituents, showing 222-, 460- 
and 320-fold selectivity, respectively. The MDR selective effect of desmosdumotins was 
partly sensitive to P-gp inhibition by verapamil in KB-VIN cells (however data were not 
shown for KB). In a later work the same group observed selective toxicity for the 3 most 




[85]. Although the difference of sensitivity between parental and MDR cell lines were 
much smaller, P-gp knockdown with siRNA resulted in the loss of cell proliferation 
blockage by the flavonoids [86]. Despite the observed P-gp mediated hypertoxicity of 
desmosdumotin B flavonoids towards KB-VIN and Hep3B-VIN, the authors noted that 
the hyperactivity of the synthesized analogues was not general against every MDR cell 
line, but they refer only to their unpublished data, without mentioning the name of the 
cell lines [84]. According to the authors the activity of these compounds is linked to 
single-nucleotide polymorphisms (SNPs) of the MDR1 gene, of which some can radically 
affect P-gp conformation, thus changing its interaction with the drugs [87]. 
In addition to small molecules, the block copolymer Pluronic P85 (P85) was also reported 
to act selectively against MDR cell lines, and the selective cell damaging effect was 
attributed to the function of P-gp [88] [89] [90]. P85 was proposed to be utilized to inhibit 
P-gp and restore the accumulation of otherwise P-gp substrate therapeutics in MDR 
cancer cells, but no convincing in vitro cytotoxicity tests were performed to clarify if P85 
alone is a cytotoxic MDR-selective agent. 
The above mentioned compounds can plausibly kill P-gp overexpressing cancer cells with 
a preference over their parental counterparts. However, in many studies the lack of 
systematic investigation of P-gp dependency of the observed collateral sensitivity leaves 
doubts about the role of the transporter, thus cell line specificity of the MDR-selective 
candidate compounds has to be delineated in later studies.  
1.3.3. Systematic study revealed MDR-selective compounds from the NCI-60 Cell 
Line Screening assay database 
The discovery that radically changed and boosted the research of anticancer collateral 
sensitivity, and when the list of known P-gp potentiated MDR-selective compounds was 
extended is tied to a systematic study, which originally meant to investigate ABC-
transporter mediated cross-resistance, and intended to predict substrates of ABC-
transporters [73]. The study used a publicly available database of the National Cancer 
Institute of the National Institute of Health (NCI of the NIH) that was created by the 
Developmental Therapeutics Program (DTP). Since its inception in 1955, DTP has 
supported the discovery of more than 40 US-licensed anti-cancer agents by providing 




worldwide [91]. The drug discovery and development services include in vitro and in vivo 
screens. The so-called NCI-60 Human Tumor Cell Line Screen was initiated in 1990, and 
utilized 60 different human tumor cell lines to identify and characterize novel compounds 
with growth inhibitory effect or tumor cell line killing potency [92]. In exchange for the 
service, DTP collected and stored the dose response data against the 60 cell lines in a 
publicly available database. In 2016, the NCI announced to close the NCI-60 screen in 
favor of launching a new repository of cancer models that are derived from fresh patient 
tumor samples with known clinical history [93]. The latest database from 2016 includes 
the toxicity values of more than 50,000 compounds [94]. One of the great advantages of 
this database is that the 60 different human tumor cell lines (representing leukemia, 
melanoma and cancers of the lung, colon, brain, ovary, breast, prostate, and kidney 
cancers) are thoroughly characterized, thus toxicity patterns can be recognized and linked 
to specific alterations occurring in cancer types [95], such as the alterations of the quantity 
or quality of resistance factors. 
The referred systematic study of Szakács et al. [73] analyzed a 1429 compound set whose 
screening data in the DTP database met a certain quality control criteria (described in 
[96]), including 118 compounds with known mechanism of action. To identify the 
compounds of the 1429 set whose toxicity was influenced by the presence of ABC-
transporters, mRNA levels of all the 48 human ABC-transporters were measured and 
correlated to the toxicity patterns disclosed by DTP. The toxicity data is stored as growth 
inhibition values, thus ABC-substrates showed strong negative correlation (the higher 
level of mRNA of a transporter the lower grade of growth inhibition). Interestingly, when 
ABCB1 mRNA levels were correlated to the growth inhibition data, several compounds 
gave strong positive correlation coefficients, suggesting that besides conferring MDR, 
ABCB1 is capable to potentiate the toxicity of certain molecules. To test this paradoxical 
observation, which seemed to be a statistically insignificant event, the authors performed 
a Benjamini-Hochberg procedure [97], which estimated that only 30% of the top scoring 
hits were false positives, and 70 % of the compounds with strong positive coefficients are 
likely to be abundant of valid correlations. After consecutive in silico filtering and in vitro 
tests, the first compound that was validated to exert hypertoxicity in various MDR model 
systems was the thiosemicarbazone NSC73306 (Figure 4). Increased toxicity of 




membrane, and when P-gp was blocked by inhibitors, hypersensitivity of MDR cells 
could be abrogated [73]. In a follow up study, the entire DTP dataset (approx. 43,000 
substances) was systematically analyzed to find more MDR-selective compounds [98]. 
As a result, dozens of compounds showing collateral sensitivity against KB-V1 cell line 
(over KB-3-1) were successfully identified, of which 4 structurally distinct compounds 
were further investigated against additional cell lines pairs, and were found to exert robust 
P-gp potentiated hypertoxicity. The new MDR-selective compounds were NSC10580, 
NSC168468, NSC292408 and NSC713048 (Figure 4). 
As thiosemicarbazones (TSCs) are known to possess a diverse biological activity profile, 
including anticancer and antiviral activity, as reviewed recently in [99], the identification 
of the P-gp potentiated MDR-selectivity exerted by NSC73306 inspired further 
investigations, and new analogues were synthesized and tested. Hall and co-workers 
disclosed a basic structure-activity relationship (SAR) study in 2 subsequent articles [100] 
[101], where residues and moieties, which increased/decreased the magnitude of the P-
gp mediated hypertoxicity of NSC73306 were identified. The most effective, improved 
TSC was ‘compound 32’ (Figure 4) showing an increased, almost 3 times higher selective 
toxicity compared to NSC73306. 
Figure 4. Verified MDR-selective compounds NSC73306, NSC10580, NSC168468, 
NSC713048 and NSC292408, identified by the systematic datamining approach. Compound 32 
[101] and Dp44mT are analogues of NSC73306 (TSCs), and KP772 (1,10-phenanthroline 




A further example of the potential of the TSC scaffold against P-gp overexpressing MDR 
cells is Dp44mT, described by Richardson et al., which mediated MDR-selective toxicity 
against the P-gp positive KB-V1 cell line [102]. As subsequent research demonstrated, 
Dp44mT showed a P-gp inhibitor (Elacridar and PSC833) sensitive hypertoxicity to KB-
V1, and also to the P-gp expressing MDR cell lines HCT-15, DMS-53 and the paclitaxel 
resistant 2008/P200A [103]. The collateral sensitivity elicited by Dp44mT seemed to be 
P-gp dependent. However, no MDR1 transfected cell lines were involved in the studies, 
thus the preferential MDR cell killing effect of Dp44mT cannot exclusively linked to the 
function of P-gp until further experiments are performed. 
TSCs are not the only compounds that were identified in several independent laboratories 
as potential MDR-selective agents. In 2007, Heffeter and colleagues identified the 
preferential and P-gp mediated hypertoxicity of KP772 towards MDR cells [104]. KP772 
is a complex of lanthanum and 1,10-phenanthroline (1,10-phen), which was capable to 
exploit the vulnerability derived from the maintenance of functional P-gp overexpression 
in the plasma membrane of the colchicine resistant KB-C1 cell line, and killed it with a 
small but significant preference over the parental KB-3-1 line. KP772 is very similar to a 
tin complex of 1,10-phen called NSC292408 (Figure 4), identified in the above referred 
systematic study as an MDR-selective compound. Moreover, as KP772 was submitted to 
the drug screening repository of DTP (renamed as NSC632737), it was identified in the 
same systematic study as a putative MDR-selective analogue of NSC292408 [98], 
supporting the relevance of 1,10-phenanthroline metal complexes. 
The list of the compounds eliciting collateral sensitivity against P-gp expressing MDR 
cells is longer and more diverse, here I only introduced examples that were relevant 
milestones (and that are related to the present PhD thesis). The observed collateral 
sensitivity was tested in different ways for each compound. In some of the presented 
studies, the role of P-gp in the preferential toxicity was not properly delineated, and still 
remains to be elucidated. The reason is partly due to the fact that collateral sensitivity 
provoking compounds were identified only by retrospective observations in experiments 
conducted with drug selected cell lines, which possibly harbor other alterations besides 
P-gp overexpression. To overcome the problem of cancer cell specific activity, systematic 
studies are preferred, as seen in the two consecutive studies of Szakács et al. [73] [98]. 




screening of compound libraries against parental and MDR cell line pairs would be highly 
beneficial. Identification of novel structures and subsequent lead optimization for better 
candidates is still an important task. 
1.4. In vitro cytotoxicity assays and HTS in drug development 
1.4.1. In vitro cytotoxicity assays to identify MDR-selective compounds 
In general, when the target of interest is a membrane transporter, membrane receptor, 
nuclear receptor or ion channel, cell-based assays are applied [105] [106]. In accordance, 
ABCB1-potentiated MDR-selective compounds reported in the literature so far have been 
identified and validated also by comparing their growth inhibitory potential against 
parental and MDR cell lines. This so called phenotype-based approach is required, as the 
exact targets of MDR-selective compounds are not known, only the function of P-gp is 
proven to be responsible for the observed effect (phenotype- versus target-based 
approaches are explained later in 1.4.2.). In vivo effects of a test compound can be 
predicted based on in vitro cytotoxicity assays. Thus, the cell-based approach is an 
important and integral step in drug discovery both for academic research and for the 
pharmaceutical industry. Validated compounds can be ranked based on their toxicity 
and/or MDR-selectivity, keeping in mind that the in vivo/clinical efficacy depends also 
on the ‘drug-likeness’ of the compounds [107]. 
There are general requirements for cytotoxicity assays. The established assay has to be 
pharmacologically relevant, which means, it has to be capable of identifying compounds 
that provoke the desired effect. It has to be reproducible across assay plates or across 
testing days. The assay must be robust: the quality of the assay has to be uninfluenced by 
the variability derived from assay methodology or perturbation introduced by the 
instruments. It is also important that solvents should not interfere with the assay output 
[108] [109]. Cost-effectiveness and safety (and the related waste management) are also 
taken into consideration during planning larger experiments [110].  
An additional relevant feature of a cytotoxicity assay in general if it is ‘robot friendly’ 
[111]. When larger compound libraries are intended to be tested in a relatively short time, 
automated liquid handling is beneficial, and 384- or 1536-well microplates are preferred. 
Thus, the assay has to be suitable for the scale down of the reaction volume to 384- or 
1536-well formats without detrimental effects on the above mentioned properties, and the 




1.4.2. Main principles of high-throughput cytotoxicity screening 
The  main  goal  of  high throughput screening (HTS)  technique  is  to  accelerate  drug  
discovery  by  screening  large  compound  libraries. HTS originates from the 1980s when 
automation, preparative chemistry, analytics and overall compound management reached 
a certain technical level allowing robust screening campaigns of good quality compound 
libraries [112]. Nowadays, the number of compounds tested in HTS campaigns are 
usually narrowed down with cheminformatics prior to in vitro tests. The in silico filtering 
step can be applied to remove problematic functionalities, to predict solubility and 
ADME-Tox properties, or to run uniqueness analysis if intellectual property issues have 
to be considered [107] [113]. 
Today HTS is a mature and validated approach to identify the chemical starting points. 
There are 2 main screening types, phenotypic and target-based approaches (Figure 5). 
 
Figure 5. Flow chart of phenotype-based and target-based drug discovery [116]. The aim of early 
phase drug discovery is to identify the target and the lead molecules. In the phenotype-based 
approach, lead molecules are obtained first, followed by target deconvolution to identify the 
molecular targets that underlie the observed phenotypic effects. In the target-based approach, 
molecular targets are identified and validated before lead discovery starts. 
 Analysis of 259 new FDA approved drugs from 1999 to 2008 suggested that phenotypic 
screening strategies were more productive in the discovery of first-in-class small-
molecule drugs [114]. However, another analysis using 113 first-in-class drugs, which 
were FDA approved between 1999 and 2013, reported that target-based approaches 
yielded more drugs [115]. The apparent contradiction, as it is explained in the latter 
article, is partly due to the different categorization of certain screens, and the conclusion 
could be biased also by the chosen drug sets, e.g. the second analysis contains many 




article is closer to the answer, both screening types are important and contribute to the 
discovery of new therapeutics. 
Selection of compounds for HTS campaigns should be well designed. Based on the 
source, chemical libraries can consist of natural products, semi-synthetic and synthetic 
compounds. If there is no known structure preference before the compound screening, 
researchers tend to use diversity sets with a high variety of chemical scaffolds and 
structures. Fragment library is used to determine biologically active compound fragments 
that can be fused to obtain more effective compounds (thus, second round of screening is 
often needed with the compounds synthesized as the combinations of the fragments). If 
there is already a promising chemotype, a focused library can be designed, that is well 
suitable also for SAR purposes and lead optimization. Historically, and for practical 
reasons, a compound library can be also ‘off-the-shelf’ relating to compounds that are 
already existing active pharmaceutical ingredients (APIs), thus compound synthesis is not 
necessary, and repositioning is possible [113]. 
There are numerous therapeutics in use that were identified through HTS. Tyrosine kinase 
inhibitors (e.g. gefitinib, erlotinib, sorafenib, dasatinib or lapatinib) are common 
examples, HTS was run in the 1990s and it took approx. 10 years for each drug to obtain 
FDA approval [117]. 
1.4.3. Role of reagent-based cytotoxicity assays in HTS 
There are a plenty of reagent-based methods to determine the cytotoxicity (growth 
inhibition) of a compound in a 96-well plate format. However, only a part of these are 
sufficiently sensitive and applicable in HTS [118]. In the practice, avoiding the usage of 
radioactively labelled materials is highly preferred due to the extra safety risks and 
disposal costs. Furthermore, the simple ‘mix and measure’ liquid handling principle is 
preferred, while filtration, separation and washing steps are to be avoided, as they are 
time consuming and difficult to automate [119]. Accordingly, cell component staining 
dyes, such as crystal violet or sulphorhodamine B (SRB) [120] are not favorable and 
limited to manual or semiautomatic screening due to the multiple washing steps and 
volatile liquid pipetting in their protocols. Similarly, the conventional MTT assay [121] 
that is probably the most broadly used viability assay, can be only augmented by 




cytotoxicity assays were utilized in compound screening, for instance the NCI-60 Human 
Cancer Cell Line Screen (see in 1.3.3.) used the SRB assay for the identification of 
anticancer compounds [122]. 
The need for HTS facilitated the development of less laborious reagent based assays with 
minimized liquid handling and incubation time. For such purposes, viability reagents 
(measuring the activity that is attributable to cellular maintenance) proved to be the most 
convenient. The MTT analogue MTS [123] provides an absorbance-based assay and 
indicates the mitochondrial reductive capacity of the cells, as the tetrazolium salt reagent 
is converted to a light absorbing formazan by living cells. Alamar Blue [124] is another 
popular viability reagent, offering fluorescent read-out. Its fluorophore called resazurin 
is converted to the highly fluorescent resorufin, mostly through mitochondrial reductases, 
similarly to MTT. Another common technique is the bioluminescent detection of ATP 
using the firefly luciferase enzyme [125], which provides a sensitive way of live cell 
(cellular energy) measurement [110] [111]. Although all these assays are assessing cell 
viability, they have relevant differences, which has to be considered in cytotoxicity 
testing. 
If reagent conversion is low (due to the small amount of viable cells), absorbance-based 
measurements are inherently less sensitive than the fluorescence- or luminescence-based 
measurements. This is because absorbance is the difference between the intensities of the 
emitted light and the light passing through the sample, which may be both very strong for 
the low concentration reagent sample and also for the control (no reagent) sample, while 
the emitted light – derived either from fluorescence or luminescence – can be 
distinguished easier from background by the detector even if the signal (reagent 
concentration) is low [126]. Another difference between the assays is in their deteriorative 
effect to cells. ATP quantification involves lysis of the cells with detergents, thus it is 
destructive and is considered as a typical end point assay. In contrast, MTS has minor 
toxicity on the cells, while resazurin based assays are not considered cytotoxic, and cells 
might be used later for additional measurements [110] [111]. However, longer exposure 
to Alamar Blue assay can hinder cell growth, as it was shown for the cisplatin resistant 




1.4.4. Examples of novel, fluorescent protein based cytotoxicity assays 
The right choice of the in vitro screening assay is of paramount importance in the drug-
discovery process. Reagent-based assays are popular and commonly used in research, as 
they are well characterized, and protocols are available and easy. However, the 
attractiveness of reagent-free and label-free approaches, and the technical improvement 
of spectrophotometers and fluorescence imaging created the possibility to quantify 
cytotoxicity in novel ways. Also, techniques that provide more information are preferred 
(e.g. high content screening) [109]. One of the novel approaches to measure cell mass is 
to exploit the light emitting nature of fluorescent proteins. Gene constructs of the 
fluorescent proteins can be inserted to host cells, allowing the establishment of 
fluorescent cell lines. Examples of fluorescent protein based, non-conventional 
cytotoxicity measurements are demonstrated in this chapter. 
In a study by Steff et al. in 2001 [128] eGFP-expressing mammalian cell lines were 
created and cytotoxicity was determined based on the decay of the eGFP signal by flow 
cytometer and also by fluorescent microplate reading, as cell death was accompanied with 
degradation of the fluorescent protein. In the same year, a more comprehensive study was 
carried out. Torrance et al. [129] used 2 isogenic DLD-1 cell lines (of which one cell line 
had a mutant K-Ras allele) transfected with either YFP or BFP, co-cultured them, and 
followed their growth for 6 days by a microplate reader via daily fluorescent intensity 
detections. They screened the effect for the growth curves of almost 30,000 compounds, 
and identified a lead compound against mutant K-Ras cell line, then confirmed its effect 
in a xenograft tumor model. High content screening (HCS) devices are also capable to 
count fluorescent protein expressing cells. In 2008 Rosado et al. [130] transfected two 
immortalized lymphoblastic murine cell line variants with either eCFP or eYFP, co-
cultured them, and tested a dozen of molecules to find selective Akt signaling inhibitors. 
The measurement of differential cell survival was performed by an automated high-
content microscopy system. In 2011 another dual-fluorescent based HCS study was 
performed, 3119 chemicals were screened against ovarian cancer cell lines [131]. One 
cell line of a pair was marked only with eGFP whilst the other was co-transfected with 
mCherry and a truncated form of the MUC16 tumor marker. After compound incubation, 
nucleus of the cells were stained with Hoechst, then plates were imaged and analyzed by 




In 2009, Brimacombe et al. [132] set up a dual-fluorescent system for probing multidrug 
resistance in cancer. They used the OVCAR-8 (parental) and NCI/ADR-RES (MDR 
phenotype) cell line pair from the NCI-60 cell panel, transfected with DsRed2 and eGFP, 
respectively. To avoid the extra nucleus staining steps, required for image based 
evaluations, co-cultured cells were investigated with a fluorescent laser scanning 
microplate cytometer, and evaluation was based on eGFP and DsRed2 intensities only. 
The same type of device was used in 2015 in the study of Kenny et al. [133] to screen the 
Prestwick Chemical Library (1140 compounds) and the Library of Pharmacologically 
Active Compounds (LOPAC1280) to identify drugs preventing adhesion, invasion and 
growth of ovarium carcinoma cell lines. Tumor cells expressing eGFP were seeded 
(simultaneously with test compounds) in a well where a multilayered culture containing 
primary human fibroblasts, mesothelial cells and extracellular matrix were already 
present. After 16 h incubation, consecutive cell fixation and washing steps, fluorescent 
cell counting was carried out, then hits were identified and taken for subsequent 
investigations. The most promising compounds were validated against ovarium cancer 
cells also in 4 different in vivo models. 
These examples show how fluorescent proteins can be used in hit and lead validation by 
cytotoxicity measurements in various ways, as appropriate alternatives to reagent based 
assays. Moreover, as apparent from some of the above examples, screening of larger 
compound libraries can be designed to rely on the fluorescent protein expression as a 
measure of growth inhibition. Cell fixation and consecutive nuclear staining had to be 
performed in some of the studies, because imaging software programs usually require it 
to distinguish (and count) cells. Therefore, washing steps could not be avoided in all 
cases, while other studies could perform a reagent-free assay procedure, which was 
beneficial in the aspect of automation. The utilization of fluorescent proteins provides 
additional benefits. Co-culturing of isogenic cell line pairs, which are different only in 
their fluorescent color can reduce the cost of culturing materials by multiplexing 
techniques, moreover cell lines in a well grow (obviously) under the same conditions. 
1.4.5. Evaluating the robustness and reproducibility of assays – Z’-factor 
Standardization is important in every part of the screening assay set-up, starting from the 
supply and maintenance of cells and other aspects of the tissue culture procedure, the 




management [110]. During assay development and optimization, statistical analysis of 
the measured data is monitored to track the assay quality. The analysis is based on 
statistical parameters such as the mean or deviation of the measured signals. Developers 
can use for instance the coefficient of variation (CV, which is the standard deviation 
normalized by the mean value) or the signal to noise ratio (SNR) to amend the assay 
performance. In addition, there is a more complex quality metrics, that is often used for 
small-molecule high throughput screens, called the screening window coefficient or Z’-
factor [134]. Z’-analysis, which determines the robustness of the assay integrates a 
number of external and internal impacts. It measures the assay resolution, which is 
influenced by many factors, e.g. by the assay procedure, or by the instrumentation that 
was used. By definition Z’-factor is a number that is ≤ 1 and the intervals of Z’-factor 
designate the usability of the investigated assay (Table 1). 
Table 1. Assay quality regarding to Z’-factor values [134]. 
Z’-factor value Related to screening Assay type 
1 An ideal assay Dose-response acquisition is possible 
1 > Z ≥ 0.5 An excellent assay Dose-response acquisition is possible 
0.5 > Z > 0 A double assay More suitable for primary screening 
0 A "yes/no" type assay Primary screening 
< 0 Screening essentially impossible   
 
Formula of Z’-factor: 
Z’-factor = [|μneg – μpos| - 3(σneg + σpos)]/|μneg – μpos| = 1 – [3(σneg + σpos)/|μneg – μpos|], 
where μpos/μneg are the mean of positive/negative controls and σpos/σneg are the standard 
deviation of positive/negative controls. Components of the formula of Z’-factor are 
visualized on Figure 6. 
Based on Table 1, screens with a simple yes/no answer as an output are acceptable if the 
Z’-factor is above 0. To be able to obtain dose-response curves, better quality assays have 
to be used, where the Z’-factor is above 0.5. As apparent from the formula and from 
Figure 6, Z’-factor reports the proportion of the assay dynamic range that is not 




cover 99.7 % of all the possible positive and negative control signals if normal 
distribution is assumed). For example a Z’-factor of 0.6 reports from an assay where 60 % 
of the assay dynamic range is not overlapping with the data variability bands. 
Accordingly, robust measurements have wider separation band size, while overlapping 
data variability bands of positive and negative controls would refer to unreliable assays. 
Nevertheless, if there are a few extreme values (outliers) in either the positive or negative 
controls, standard deviation will increase and it can affect the Z’-factor, potentially 
leading to an apparently unfavorable Z’-value, even when the assay would perform well 
[135]. 
Figure 6. Graphical definition of Z’-factor. Z’-factor calculation is based on the measured mean 
and deviation of the positive and negative controls, which return the lowest and highest values 
that can possibly be measured. Z’-factor is the ratio of the separation band and the assay dynamic 
range. (The formula consist the assay dynamic range in an absolute value as depending on the 
assay type, either positive or negative controls can return the highest/lowest possible signal.) 
1.4.6. Hit identification by assays based on fluorescent protein expression  
Besides finding the active substances from a screen, exclusion of false positive hits (not 
truly active substances) and false negative hits (missed active substances) are also part of 
the hit identification process. While with an appropriate Z’-factor it is possible to keep 
the number of false hits low, there are assay specific factors, which can disturb the 
integrity of the data. In the case of fluorescent protein expressing cell lines, disturbance 
of compound screening might derive from unspecific gene expression change due to the 
applied DNA transfection procedures, or from the usage of inherently fluorescent 
compounds. Thus, it is advisable to use a counter assay in the follow-up studies for at 
least the best hit compounds, and when possible, to use repeats during the screen [136] 





Overcoming P-gp-mediated cancer multidrug resistance is still a serious obstacle. A 
possible solution could be the application of so called MDR-selective agents, which target 
P-gp overexpressing tumor cells. However, proof-of-concept in vivo studies are still 
missing, the attempts reported inactivity of compounds, which is plausibly due to the 
unfavorable pharmacokinetics and the low MDR-selectivity of the tested agents. Thus, 
our overall aim was to establish a screening platform for the robust and high throughput 
identification of MDR-selective compounds at the scale of an academic research group, 
to find drug-like candidates for iterative lead optimization. Identification of novel MDR-
selective compounds would broaden our knowledge on the nature of the P-gp potentiated 
MDR-selective mechanism, which would supply SAR models intended to predict even 
more potent, pharmacologically active candidates. 
Objective #1. Establishment of a standardized cytotoxicity testing system amenable 
for high throughput screening of compound libraries 
#1A. Design of a 3-step compound screening system including primary, confirmatory and 
secondary screening. 
#1B. Introduction of a reagent free, fluorescent protein based cytotoxicity assay 
measuring growth inhibition. 
#1C. Robotization of the screening procedure and automated data evaluation 
implemented for both 96 well and 384 well plate experiments to increase compound 
throughput. 
Objective #2. Identification and validation of MDR-selective compounds guided by 
literature data 
#2A. Verifying the putative MDR-selective toxicity of compounds reported to 
preferentially kill P-gp overexpressing MDR cell lines. 
#2B. Systematic identification of novel MDR-selective compounds from the NCI DTP 
drug repository database. 
#2C. Defining chemotypes linked to MDR-selective cytotoxicity, based on #2A and #2B. 
Objective #3. Screening of focused libraries designed to investigate the chemical 




3. Materials and Methods 
3.1. NCI DTP database and in silico data mining 
The in silico data mining was performed using the NCI-60 Cell Line Screen database 
released in December, 2010, which is available at the DTP website [94]. The algorithm 
we used was the same that our group used before on an earlier release [73] [98]. Briefly, 
we determined the Pearson’s coefficient between the pGI50 values of each DTP chemical 
entity measured against the NCI-60 cell line panel and the mRNA expression of ABCB1 
of the NCI-60 cell lines. We filtered out uninformative drug profiles, where >50% of the 
60 possible values were either missing or indicated inactivity, and collected the in silico 
hits with a coefficient higher than 0.4, thus when high drug sensitivity was accompanied 
with high ABCB1 expression, which is characteristic of the P-gp mediated MDR-
selective compounds. 
3.2. Compounds and chemicals 
Unless otherwise stated, chemicals were purchased from Sigma Aldrich (Merck). NSC 
compounds were acquired from DTP's drug repository, except NSC733435, which was 
purchased from ChemBridge Corp. Desmosdumotin analogues were synthesized by 
Szintekon Ltd. Pluronic P85 was a kind gift from Dr. R. Mészáros (ELTE University, 
Hungary). Tariquidar was a kind gift from Dr. S. Bates (NCI, NIH). KP772 was 
synthesized by our colleague, Veronika F.S. Pape as described by Hart and Laming with 
slight modifications [139]. Compounds of the protoflavone library was synthesized and 
provided by the group of Dr. Attila Hunyadi (SZTE, GYTK, Szeged). Compounds of the 
library containing flavonoids and thiosemicarbazones were synthesized and provided by 
Ahcène Boumendjel (Univ. Grenoble Alpes, Département de Pharmacochimie 
Moléculaire, France). Library of the thiosemicarbazones and their analogues was 
designed by Veronika F.S. Pape, who also synthesized several substances of the library, 
while other compounds were either obtained from DTP or were purchased from 
commercial sources. 
Dissolved compounds of the liquid library were stored in 1.1 ml tubes in 96 position 
racks, where tubes could be collected for the experiments individually, while mother 
plates (96 well polypropylene trays) had fixed layouts with 36 compounds in 2 




Structure of compounds were sketched by Marvin (ChemAxon Ltd.). 2D structural 
clustering was performed with PubChem’s Chemical Structure Clustering Tool [140], 
which uses the Single Linkage algorithm, and draws the dendograms based on the 2D 
Tanimoto similarity index. 
3.3. Cell lines and culture conditions 
The following cell lines were used in the experiments: 
 MES-SA uterine sarcoma cell line and its doxorubicin selected derivative MES-
SA/Dx5 (referred only as Dx5 from here) were purchased from ATCC. MES-SA 
mCherry and Dx5 mCherry cell lines were created using lentiviral transduction by 
Creative Cell Ltd., Budapest. Cells that were expressing mCherry stably were 
sorted with a Beckton Dickinson FACS Aria cell sorter. 
 A431 human skin-derived, epidermoid carcinoma cell line was purchased from 
ATCC. The retrovirally transduced A431-B1 and A431-G2 cells were established 
earlier [141] [142]. 
 OVCAR-8 (OVC-8) DsRed2 and NCI/ADR-RES eGFP ovarium carcinoma cell 
lines were a kind gift from Dr. Michael M. Gottesman (National Institutes of 
Health, US). The respective expression vectors encoding the fluorescent proteins 
DsRed2 and eGFP were transfected by Lipofectamin2000 reagent. 
 KB-3-1 cervix carcinoma cell line and its vinblastine selected derivative KB-V1 
were a gift from Dr. Michael M. Gottesman (National Institutes of Health, US). 
 MDCK II (Madin-Darby canine kidney cell line) was obtained from ATCC. MDCK 
II B1 cell line stably expressing the human wild-type ABCB1 was created by the 
Sleeping Beauty transposon-based gene delivery system, using the 100 × 
hyperactive SB transposase [143]. 
 HCT-15 cell line was obtained from DTP (DCTD Tumor Repository, National 
Cancer Institute at Frederick, US). 
 KB (nasopharyngeal carcinoma) and KB-VIN (vincristine-resistant KB subline) 
cell lines were a generous gift of Dr. Y.-C. Cheng, Yale University, US. 
 DMS 114 small cell lung carcinoma and the nintedanib resistant DMS 114-NIN 





Cell lines were maintained either in DMEM (Mes-Sa, KB-3-1, A431, MDCK II and DMS 
114, and their derivative cell lines) or in RPMI (OVC-8 DsRed2, NCI-ADR/RES eGFP 
and HCT-15) completed with 10% FBS, 5 mM glutamine and 50 units/ml penicillin and 
streptomycin (Life Technologies). KB and KB-VIN cell lines were maintained in RPMI 
medium completed with 10% FBS, 25mM HEPES and 100 µg/ml kanamycin as it was 
indicated in the literature [85].  Cells were periodically tested and resulted negative for 
mycoplasma contamination with the MycoAlert mycoplasma detection Kit (Lonza). 
Drug selected cell lines Dx5 and Dx5 mCherry were treated with 500 nM doxorubicin 
prior to the experiments, while KB-V1 and KB-VIN cell lines were selected in 300 nM 
vinblastine and 100 nM vincristine, respectively. 
3.4. Cytotoxicity assays using MTT, PrestoBlue or SRB reagents 
Cells were seeded in a 5000 cells/well density on 96-well plates in 100 µl, except for 
MDCK II cells that were seeded in 2500 cells/well density due to their high proliferation 
rate. After cell attachment, serially diluted compounds were added to the wells in a final 
volume of 200 μl, then plates were incubated until measured. When inhibitors (TQ: 1 µM, 
PSC833: 2 µM) were used to block P-gp, 4-times concentrated solutions were added to 
the 100 μl cells in a volume of 50 μl, few minutes before adding 50 μl of the test 
compound. 
When viability was measured by MTT, the medium was removed before adding the 
tetrazolium salt dissolved in PBS (0.5 mg/ml). Plates were incubated for 4 hours, then 
formazan crystals were dissolved in isopropanol-HCl (9:1) using 1 M HCl, and 
absorbance was obtained at 540 nm. When PrestoBlue cell viability reagent was applied, 
we diluted the dye in PBS (5-10 %) and exchanged the medium in the wells to it, and 
incubated the plates for 1 hour. The fluorescence of the dye was obtained with 555ex/585em 
wavelengths. SRB assay was carried out by following the manufacturer’s instruction, 
using a 0.4 w/v % solution. We used the 540 nm filter to measure absorbance and the 
660 nm filter to measure background absorbance. For negative controls, we used the wells 
with untreated cells. For positive controls, we used cell-free wells in the case of MTT and 
PrestoBlue, while for SRB, we used the wells, where devastating concentrations of drugs 
were applied, to exclude the error deriving from cell debris. 




Multilabel plate reader, while PrestoBlue assay was detected by a monochromator based 
EnSpire Multimode plate reader (both readers are the product of Perkin Elmer). As 
solutions were homogenous, all the 3 assay types were read with top reading mode and 
with single point measurements. 
3.5. Fluorescent protein based cytotoxicity assays 
OVCAR-8 DsRed2 and NCI/ADR-RES eGFP cell lines were tested in 96 well plates, 
seeded in a density of 5000 cells/well. After cell attachment and drug addition, plates 
were incubated for 144 hours, which was interrupted only for short times, when the plates 
were measured at certain days prior to the final measurement at day 6 (144 h). Based on 
literature data [132], we applied a 540 nm – 579 nm filter set (excitation and emission, 
respectively) to measure the fluorescence of the wells where DsRed2 expressing cells 
were seeded, and 485 nm - 535 nm filter set to measure eGFP by a Victor X3 Multilabel 
plate reader. 
On the purpose of cytotoxicity testing, Mes-Sa mCherry and Dx5 mCherry cell lines were 
seeded in a density of 5000 cells/well on 96 well plates, and 2500 cells/well on 384 well 
plates in 100 μl and 20 μl of medium, respectively. The following day, the liquid handling 
machine (Hamilton Microlab StarLet workstation) prepared serial dilutions, and 
dispensed the test compounds on the plates according to the plate maps. The final volume 
of the assay was 200 μl in a 96 well plate and 60 μl in a 384 well plate. Microplates were 
incubated, and the fluorescence was measured at 585ex/610em wavelengths on certain 
days, most frequently at 72 h and at 144 h by the EnSpire Multimode plate reader, where 
the excitation wavelength is produced by a monochromator. When eGFP or mOrange 
expressing cells were measured, we used protocols with 545ex/567em and 485ex/510ex 
wavelengths, respectively. Values - obtained from bottom reading mode - were 
normalized to the untreated (negative) control and to wells, where all cells were killed 
(similarly to SRB assay), as the relative fluorescent value of this positive control was 
different from values of cell-free wells containing only medium. 
As for culture plates, we used clear walled polystyrene microplates in the cytotoxicity 
experiments, both when 96 or when 384 well formats were applied. The 96 well plates 
were purchased from various sources (e.g. from TPP Techno Plastic Products AG,  




compound set/focused library was assayed on plates from a single vendor, while 384 well 
plates were all obtained from Greiner Bio One International GmbH. 
Cytotoxicity (IC50 or GI50 values) were obtained by sigmoidal curve fitting by the 
GraphPad Prism software using the four parameter logistic equation with automatic top 
(cf. negative control) and bottom (cf. positive control) plateau determination: 
Y = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)), 
where Y: measured values 
 X: corresponding concentration 
 Bottom: value of the bottom plateau of the curve 
 Top: value of the top plateau of the curve. 
Alternatively, automated data evaluation was performed by our custom program, which 
was written by Judit Sessler in C#, and half-maximal growth inhibition was calculated 
based on nonlinear least square regression (nls) of the logistic function: 
nls (y = 1/ (1 + exp (-b * (x -c)))) 
where y: measured values 
 x: corresponding concentration 
 b: Hill slope 
 c: log IC50. 
The source of the automatic data processing was the raw plate reader output file which is 
in a text (.txt) or in a comma separated values (.csv) format. To visualize the results for 
quality check, the program is using the graphical surface of the ‘R’ software environment. 
3.6. Flow cytometry 
3.6.1. Analysis of mCherry expressing cell line populations 
The expression level of the mCherry fluorescent protein in cells and the proportion of the 
fluorescent protein containing population were analyzed by an Attune Acoustic Focusing 
Cytometer (Thermo Fisher Scientific) in cell culture medium. Cell lines expressing 
mCherry were excited with a violet laser at 405 nm, and detected in the Violet Laser 3 




3.6.2. Calcein-AM efflux assay 
After detachment with trypsin 250,000 cells were collected in serum free medium in test 
tubes, and incubated with 0.25 mM Calcein-AM (Dojindo Molecular Technologies) with 
or without 50 μM verapamil for 10 minutes at 37°C. The uptake was stopped by adding 
ice-cold PBS, tubes were centrifuged, then cells were re-suspended in ice-cold PBS and 
stored on ice until measured by the Attune Acoustic Focusing Cytometer. The forward 
and side scatter density plot (FSC-SSC plot) was used to discriminate cell debris, and 
cells without intact membrane were excluded based on staining with Zombie Violet Dye, 
which was excited at 405 nm and detected in the Violet Laser 1 channel (VL-1; 430-
470 nm). To measure the calcein accumulation of cells, the samples were excited at 
488 nm with a blue laser, and the signal of calcein was detected by using the Blue Laser 1 








First, I describe the introduction, automation and characterization of the fluorescent 
protein based cytotoxicity assay system (4.1). The assay development is followed by the 
verification of reported MDR-selective agents and a systematic datamining from a 
publicly available database, all in order to identify structures related to P-gp potentiated 
hypertoxicity (4.2). In the third part (4.3), results of focused library screening are 
presented. 
4.1. Establishing an automated cytotoxicity testing platform capable of HTS, 
combined with a fluorescent protein based cytotoxicity assay development 
In this chapter, I describe the development of the screening algorithm together with the 
fluorescent protein based cytotoxicity assay. Results of the drug screens will be shown in 
chapters 4.2 and 4.3. 
4.1.1. Establishing a 3-step screen to for the identification of MDR-selective 
compounds 
One of our primary goals (objective #1A) was to introduce a compound screening system, 
which has a higher throughput in order to be able to test larger compound libraries, and 
to discover potent MDR-selective agents. Accordingly, to achieve our aim, we designed 
a 3-step small molecule screening system that is suitable for HTS purposes, and facilitates 
lead selection for further optimization. The 3 steps to be accomplished were: (1) primary 
screen, (2) confirmatory screen and (3) secondary screen (Figure 7). 
The goal of the primary screen was to identify and exclude nontoxic or low activity 
compounds. The primary screen we developed was probing the unknown compounds in 
2 concentrations (10 μM and 100 μM) against 2 cell lines (a parental and MDR 
derivative). The results were interpreted simply as growth inhibition normalized to the 
live and dead controls, ranging ideally between 0 and 100 %. The 2 concentrations per 
cell line allowed us to classify and prioritize the compounds. The 9 classes provided some 
degree of flexibility in determining the set of interesting compounds, which were chosen 






Table 2. Cytotoxicity classes derived from the primary screen. A compound was 
considered toxic if its growth inhibition was higher than 50 %. CS: collateral sensitivity. 
 
 P-gp expressing MDR cell line (e.g. Dx5) 
   
toxic at 
10 μM 
toxic only at 
100 μM 




























For both substrates and collateral sensitivity provoking agents, category I possessed 
compounds, which were not toxic to one of the cell lines at 100 μM but killed the other 
already at 10 μM. Category II possessed compounds killing one cell line at 10 μM, while 
killing the other only at 100 μM. Category III possessed compounds, which killed a cell 
line only at 100 μM and was inactive against the other line. Intermediately toxic 
compounds killed both cell lines only at 100 μM. In the primary screen, every compound 
that was toxic at 100 μM in at least one of the cell lines was considered as a hit. The 
prioritization of the hits based on the categories shown in Table 2 (cytotoxicity classes) 
was not needed when smaller compound libraries were tested – in that case non-toxic 
compounds were excluded from further investigations. In the case of larger compound 
libraries, cytotoxicity classes were used to control the amount of compounds to be probed 
in multiple concentrations, thus beyond the non-toxic substances, some hits might have 
been excluded as well. 
We used the two-point growth inhibition data derived from the primary screen to estimate 
the concentration interval to be used in the second step, the confirmatory screening, where 
the primary hit compounds were probed against the same cell lines, but in a serial dilution 
in DMSO, consisting of 7-9 concentration points, depending on the plate layout. To 
minimize the error of missing the full dose response curves, broader concentration 
intervals were used for the confirmatory screening. The hits that were interesting also in 
the second step, e.g. compounds whose dose-dependent MDR-selective toxicity was 




screening step we planned to utilize cytotoxicity assays that work by a different principle 
than the assay in the primary and confirmatory steps (a counter assay), and to involve 
additional cell line pairs in order to test the robustness of the observed cytotoxic effect. 
In the secondary assay step, drugs were diluted in cell culture medium. The workflow of 
the 3-step process is shown on Figure 7. 
 
Figure 7. Scheme of the multistep screening process we developed to identify potent MDR-
selective compounds. The potency (cytotoxicity and cell line selectivity) of the tested drugs were 
investigated after each step, based on the information (info) shown in the respective boxes to 
choose lead (or lead-like) compounds. 
4.1.2. Utilization of fluorescent protein expressing cells in cytotoxicity testing  
The next task was to choose a cytotoxicity assay for the primary and confirmatory screens, 
keeping in mind that it has to be suitable for HTS. Thus, the main aspects we considered 
was the simplicity of the assay procedure and long term cost effectiveness. We used 
genetically engineered cell lines that express fluorescent proteins (under a constitutive 
promoter) to introduce a reagent free method. Fluorescent cells were seeded in 
microplates, and cell numbers were estimated based on fluorescent intensity. To establish 
and validate such a fluorescent protein based cytotoxicity assay (objective #1B), we used 
the OVCAR-8 DsRed2 and NCI-ADR/RES eGFP cell lines, which were engineered and 
characterized by the research group of Michael M. Gottesman [132]. These two cell lines 
stably express the fluorescent proteins and their growth characteristics are identical to the 
corresponding non-fluorescent cells in the period of a cytotoxicity assay. 
The first criterion was to find a linear correlation between the cell number and the 
fluorescent intensity measured by the plate reader. By using the appropriate filter 




is relevant in the cytotoxicity assays, we defined a proportional relation between the 
actual cell number and the fluorescence of a well on the microplate (Figure 8). Thus, the 
mere presence of the intracellular fluorescent proteins was sufficient for measuring the 






Figure 8. Fluorescent intensity (relative fluorescent unit, RFU) as the function of the number of 
OVC-8 DsRed2 and NCI/ADR-RES eGFP cells (panel A and B, respectively). Dotted lines 
represent the linear fit with a coefficient of R2. 
As a next step, we checked the growth rate of the cell lines. In contrast to end-point assays, 
the fluorescent protein based measurement is not harmful to the cells (it is ‘quasi label-
free’), thus we measured the same plate each day. The fluorescent signals of DsRed2 and 















































Figure 9. Normalized growth kinetics of the fluorescent cell lines OVC-8 DsRed2 (red line) and 
NCI/ADR-RES eGFP (green line) in a 144 h long experiment. 
Based on the above experiments, we can reliably measure and follow the number of cells 
in time. Thus, we have to be able to measure if growth is hindered or inhibited by a given 
test compound. To see how growth inhibition changes over time, we conducted a 
cytotoxicity assay, where each day the same plate was measured for DsRed2 and eGFP 
fluorescence (Figure 10). As a test compound NSC73306 was chosen because of its 
known MDR-selective cytotoxic effect [73]. NSC73306 showed concentration dependent 
growth inhibition of OVC-8 DsRed2 and NCI/ADR-RES eGFP cells. For both cell lines 
100 μM of the compound caused complete inhibition of growth, and fluorescence signal 
was slightly decreased by 144 h referring plausibly to the degradation of the fluorescent 
proteins as a consequence of cell death. At 3.13 μM NSC73306 hindered both cell lines 
in their growth, and this effect was much more pronounced in the MDR cells, proving the 
MDR-selective toxicity of this compound. The untreated cells had identical growth rates 
as cells seeded in wells where NSC73306 were present in non-toxic concentrations. 
 
 





















Figure 10. Growth curves for (A) OVC-8 DsRed2 and (B) NCI/ADR-RES eGFP treated with 
various concentrations of NSC73306 for 144 h. RFU values of the untreated control and two 
concentrations of the NSC73306 are connected with a line to highlight the change in cell number. 
When we normalized the raw fluorescent values of each day separately, where 0 % 
referred to the complete growth inhibition (when 100 μM NSC73306 was applied) and 
100 % referred to the untreated control, we could draw dose-response curves (Figure 11), 
and determined the cytotoxicity by calculating the half maximal growth inhibition (GI50) 
values (Figure 12/B). 
NCI/ADR-RES eGFP






















































































































































Figure 11. Dose-response curves with sigmoidal fit for NSC73306 obtained over 6 days (at 24-
48-72-96-120-144 h in figures A-B-C-D-E-F, respectively. Red curves: OVC-8 DsRed2, green 
curves: NCI/ADR-RES eGFP. 
The toxicity of NSC73306 was increasing till 96 h for OVC-8 DsRed2 cells, when 
toxicity apparently started to slightly decrease. For NCI/ADR-RES eGFP cells 
cytotoxicity was increasing in the whole period of the experiment. As a consequence, the 




As the fluorescent protein based assay was not harmful to the cells, we were able to 
perform a conventional MTT assay after the 144 h fluorescent measurement. The 
obtained half maximal inhibitory concentration (IC50) values and also the selectivity ratio 
(SR) were a bit lower than that of the corresponding fluorescent measurements 
(Figure 12). 
A)      B) 





















Figure 12. A) Dose response curves for NSC73306 measured with MTT assay after 144 h drug 
incubation. B) Table of GI50 (and IC50 for MTT) values of NSC73306 in μM, and selectivity ratio 
(OVC-8 DsRed2 divided by NCI/ADR-RES eGFP). 
To avoid daily measurements for 144 h in the further use of the fluorescent protein based 
assay (which would include weekends) and to reduce measuring time, normalization of 
the data and drawing dose-response curves at certain time points seemed a better solution 
to find selectively toxic agents than comparing growth curves for each concentration 
points (which was the case in [129], where 6-days growth kinetics were compared). The 
separate GI50 values are clear interpretations of the grade of inhibition, which is easier to 
quantify and handle, while for growth kinetics, raw data collected on different days must 
be linked, making the evaluation more complex and more prone to mistakes. As common 
cytotoxicity procedures deal with 72 h incubation time of drugs on cells, we decided to 
measure plates at this customary time as well as at 144 h where selectivity of NSC73306 
was the highest. In this way, we decreased the number of measurements to 2 instead of 7 
that would be necessary to obtain growth kinetics in a 144 h measurement.  
We investigated two ABCB1 substrates, vinblastine and morpholino-adriamycin, and 
another MDR-selective compound NSC693871 [98] to support the utility of this novel 
microplate based cytotoxicity assay. Both ABCB1 substrates killed the parental OVC-8 
time of OVC-8 NCI/ADR- Selectivity 
measurement DsRed2 RES eGFP Ratio 
24 h 12.4 11.4 1.1 
48 h 9.0 5.2 1.7 
72 h 4.8 2.6 1.8 
96 h 4.3 2.3 1.9 
120 h 4.9 2.1 2.4 
144 h 5.3 2.1 2.5 




DsRed2 cell line in low concentrations of the drugs, but killed the MDR-cell line only at 
extremely high concentrations (Figure 13 and 14). In contrast, NSC693871 conferred a 
well apparent MDR-selectivity at 72 h and 144 h time points (Figure 15). Our results 
suggest that the fluorescent protein based assay that we adapted is suitable to test the 
cytotoxicity of compounds via growth inhibition, and we are able to identify the resistance 
of MDR cells to ABCB1 substrates and also the MDR-selective toxicity of certain 
compounds. 





































Figure 13. Cytotoxicity of vinblastine measured with the fluorescent protein based assay (A) at 
72 h and (B) at 144 h. 





































Figure 14. Cytotoxicity of morpholino-adriamycin (NSC354646) measured with the fluorescent 









































Figure 15. Cytotoxicity of NSC693871 measured with the fluorescent protein based assay (A) at 
72 h and (B) at 144 h. 
Following validation of the fluorescent protein based assay, we tested several compounds 
with unknown cytotoxic activity against the OVC-8 DsRed2 and NCI/ADR-RES eGFP 
cell lines. The assay development is demonstrated prior to the results of compound library 
testing (according to Objective #1 and #2-#3), and the respective growth inhibition values 
are shown in Table 12 (4.2.2.1). 
4.1.2.1. Statistical approach to qualify the fluorescent protein based assay 
The next step was to decide if the established fluorescent protein based assay is amenable 
to be utilized in high throughput screening (HTS). In general, an assay can be automated 
for HTS if the Z’-factors (calculated from positive and negative controls from each assay 
plate) is above zero. The higher Z’-factor the more reliable the assay is. Accordingly, an 
assay with a Z’-factor over 0.5 allows already to investigate dose dependency instead of 
a yes/no type of assay (Table 1; [134]). 
The data from all the cytotoxicity assays performed with OVC-8 DsRed2 and NCI/ADR-
RES eGFP cell lines measured at 72 h and/or at 144 h were collected, and Z’-factors were 
retrieved. These Z’-factors, depicted on Figure 16, were calculated from the controls of 
each cytotoxicity plate, and represent the reliability of the individual measurements. 
Based on the Z’-values, the fluorescent protein based cytotoxicity assay conducted on 96 
well plates performed well, both when DsRed2 and when eGFP was measured. Some 
individual assay plates although returned a Z’-factor of smaller than 0.5, thus in those 
certain cases the dose-dependence data had to be checked, and the experiments were 




from data evaluation. As the average Z’-factor was above 0.5, which is the category of an 
excellent assay based on Table 1, the cytotoxicity data we obtained was reliable at both 
time points (Table 3). 
 
Figure 16. Z’-factors per experiment for OVC-8 DsRed2 (red dots) and NCI/ADR-RES eGFP 
(green dots) measured at 72 h and at 144 h. Each dot represents the reliability of the measurement 
from a single 96 well plate. 
Table 3. Average and standard deviation of Z’-factors calculated from the fluorescent 
protein based measurement performed on 96-well plates. 
Cell line 72 h 144 h 
OVCAR-8 DsRed2 0.76 ± 0.16 0.87 ± 0.12 
NCI/ADR-RES eGFP 0.72 ± 0.21 0.84 ± 0.13 
 
4.1.3. Installation of an automated screening platform to perform fluorescent 
protein based cytotoxicity assays on 96 and 384 well plates 
The fluorescent protein based cytotoxicity assays against OVC-8 DsRed2 and NCI/ADR-
RES eGFP cell lines were all performed manually. The throughput (no. of tested 
compounds in a given time) of manual testing was relatively low, and the possibility of 




















Our aim (objective #1C) was to reach an advanced level in cytotoxicity testing by the 
robotization of the assay procedure combined with automatic data evaluation. 
4.1.3.1. Items of the screening platform 
In order to increase the throughput and test larger compound libraries in search for potent 
MDR-selective agents, automation of liquid handling was indispensable. Therefore we 
installed a Hamilton StarLet automated liquid handling machine and wrote various 
methods (programs in the Venus2 software) to seed cells on culture plates, to perform 
serial dilutions and to perform liquid transfer of the dissolved drugs for primary, for the 
confirmatory and for the secondary screening steps. As the methods operate with fix deck 
layouts, all plate maps had to be standardized and pre-defined by considering also the 
possible robot specific pipetting channel movements. Example plate maps are shown in 
the supplement (Appendix 2). 
As a part of the screening platform, we purchased also a Perkin Elmer EnSpire multimode 
plate reader that was dedicated mostly for our screening purposes. The EnSpire protocols 
were created according to the pre-defined plate layouts that were used for the Hamilton 
methods. After the desired incubation time of the cytotoxicity tests, microplates were 
measured by the plate reader. Plates could be loaded either manually or automatically, as 
the robot and the reader were connected and capable of information exchange. 
4.1.3.2. Creation of a fluorescent cell line deposit 
We validated the fluorescent protein based cytotoxicity assay for OVC-8 DsRed2 and 
NCI-ADR/RES eGFP cell lines. However, for compound screening we intended to use 
other cell lines as well. In cooperation with the research group of Dr. Katalin Német 
(Creative Cell Ltd.) and with the help of my colleagues, especially of Nóra Kucsma, we 
created a fluorescent cell line deposit, which we still continuously expand. The deposit 
consists of cancer cell lines from different tissues of origin. Lentiviral transduction of a 
pRRl-EF1 plasmid containing the gene of the fluorescent protein was followed by sorting 
for fluorescence (at least twice) by a flow cytometer (BD FACS ARIA). Examples of 






Table 4. Fluorescent cell line deposit with the respective virus titer for 3*10^4 cells. 
Parental and MDR variants of the cell lines were grouped together. 
Cell line eGFP mOrange mCherry 
A431 25 μl     
A431 B1     25 μl 
A431 G2   5 μl 25 μl 
Mes-Sa 25 μl; 50 μl 10 μl 25 μl; 100 μl 
Mes-Sa B1 25 μl 25 μl 100 μl 
Dx5 25 μl 10 μl 25 μl; 100 μl 
KB-3-1 5 μl; 25 μl     
KB-V1     5 μl; 25 μl 
MDCK II 5 μl     
MDCK II B1     5 μl 
 
4.1.3.3. Compound registry 
To conduct the HTS fluently, incoming compounds were registered in a systematic way. 
We created a database, where the amount of compounds, disposition of 
powders/solutions, etc. were stored, to make them easily accessible for testing. Structural 
information was also entered, which was connected to the Instant JChem software 
(ChemAxon Ltd.), allowing structural search for uniqueness identification of new 
molecules (Figure 17). 
 
Figure 17. Flow chart of compound registry. Upon compound arrival, all physical and chemical 
data (e.g. amount of compounds, or structures as smiles) were collected and entered to an excel 
file, where an internal code was assigned to each compound. The compound registry was 
uploaded to a database, which stored and matched the corresponding biological data. The plate 




4.1.3.4. Automated raw data processing 
The automation of liquid handling in primary, confirmatory and secondary screening, and 
the throughput increment lead to an increasing amount of raw data to process. The 
solution for the “data boom” relied on our custom made in house software that read and 
processed the raw data files from the microplate reader (written by Judit Sessler). When 
the automated GI50 calculations were compared to the individual curve fitting by 
GraphPad Prism with a compound set of 80, the differences were negligible (Appendix 
3), thus we considered the automated technique reliable. The growth inhibition values 
were stored in the same database where the compounds were registered, thus linking 
biological data to chemical features were also available. 
4.1.3.5. Optimization of fluorescent protein based cytotoxicity screening with 
mCherry expressing uterine sarcoma cell lines 
For compound screening we worked predominantly with the uterine sarcoma cell line pair 
Mes-Sa and Dx5, both transfected with mCherry fluorescent protein. Mes-Sa and Dx5 
cells are easier to handle compared to other cell line pairs we used, and the fluorescence 
of mCherry did not interfere with the fluorescence of the calcein dye, that is commonly 
used to check the distribution of P-gp expression in a cell population [144]. 
In the preparatory phase, several cell lines were created with different levels of 
fluorescent protein expression, partly as a consequence of lentiviral transfection 
optimization, as the virus titer (based on the efficiency of transfection) can be different 
for each cell lines, and partly because the sufficient fluorescent protein level in the 
cytoplasm that is required for reliable detection of cell mass with the EnSpire plate reader 
was unknown. Thus, we characterized initially 3 mCherry expressing cell lines, Mes-Sa 
mCherry, and 2 variants of Dx5 mCherry, one with low and one with higher fluorescent 
protein expression, in order to choose the appropriate fluorescent protein level. (Dx5 cells 
with low and high expression profile were created by 4-fold difference in the amount of 
viruses used for transfection; Table 4). All the 3 cell lines were expressing mCherry stably 
and homogenously (Figure 18/A). We investigated if the lentiviral transduction of 
mCherry induced any change in the P-gp expression of the cell lines. Therefore, we 
performed a calcein uptake assay [144]. Mes-Sa mCherry accumulated the calcein dye, 
which was unaffected when verapamil was present, showing that Mes-Sa remained P-gp 




calcein-AM, preventing its intracellular cleavage to the fluorescent calcein form, while in 
the presence of verapamil, calcein-AM accumulation was restored (Figure 18/C and D). 
A)  
B)    C)    D) 
  
Figure 18. A) Fluorescent intensity of mCherry expressing Mes-Sa (yellow) and two variants of 
Dx5 mCh (green and red). Control cells were non-fluorescent Mes-Sa (purple) and Dx5 (blue). 
Calcein-AM efflux assay of (B) Mes-Sa mCh and (C, D) Dx5 mCh cells (higher mCherry 
expressing variant on panel C and the faint variant on panel D), graphs show unstained cells (red), 
calcein-AM treated cells (green) and calcein-AM treated cells pre-incubated with verapamil 
(blue). 
After proving that the automated pipetting did not do any harm to the cell lines (Appendix 
5), we had to optimize the plate reading protocols regarding to the special characteristics 
of the fluorescent proteins and of the cell lines expressing them. The first set of the 
fluorescent based cytotoxicity experiments - such as the first screening - were conducted 
on 96 well plates. During the fluorescent assay development measuring mCherry we 
created 3 different plate reader protocols for the 96 well plate layouts. 
In the beginning, we used two microplate reader protocols, where flash number, which 




of measuring time. Albeit the measurement with 1250 flash number showed better 
performance (Z’-factors), the coherence of data derived from these measurements were 
far from what we expected and what we observed previously during the adaption of this 
assay type, when DsRed2 and eGFP expressing cell lines were measured with another, 
filter based plate reader. Thus, after the first set of experiments, we started to examine the 
effect of the uneven 2D distribution of the cells on the bottom of the well, and its influence 
on assay reliability. 
4.1.3.6. Uneven distribution of cells 
When cells are seeded in 96 well plates, their distribution can change over time. For 
certain cell lines, uneven distribution occurs soon after attachment, and cells tend to 
migrate closer to the wall of the wells, which is even more pronounced in the case of outer 
wells. If cells proliferate during incubation time, they occupy the middle of the well only 
if the sides around are already confluent or even overgrown. This effect is well observed 
in the case of the uterine sarcoma cell lines we used (Figure 19). 
 
Figure 19. Distribution of Dx5 mCherry cells in a 96 well plate after 72h incubation. Images were 
taken with the JuLi Stage real-time fluorescent microscope (NanoEntek) by Veronika Nagy. 
Because of the uneven distribution of the cells, single point measurement protocols (with 
1000 or 1250 flashes), which focused the exciting light beam in the middle of the well 
could not measure the cell mass appropriately. By using the ‘well area scan mode’ 
available in the EnSpire reader, we could tailor our measurement protocol by choosing 
the scanned area and considering the special growth feature of the cell lines. Accordingly, 
we divided the 1250 flashes into a 5 scan points per well protocol (5x250 flashes). Four 
points measured cells on the side of the well and one point in the middle. The location of 




Distance between the points were set to 2 mm based on the morphology of the cell 
cultures. 
A)       B) 
 
Figure 20. A) Heat map showing the distribution of Mes-Sa mCherry cells in the wells of a 96 
well plate measured by the plate reader in scan mode (5 points/well) after 72h incubation time. 
Column 2 from well E to H and the whole column 12 is the background (dead cells). Green refers 
to lower fluorescence (lower cell numbers), and the more orange refers to higher fluorescence, 
thus higher cell density. B) Individual relative fluorescent intensity units (RFU) of the scanned 
points demonstrate the 2D cell distribution within wells A1, A7 and H8. Each of the 5 RFU values 
were measured with 250 flash numbers. 
4.1.3.7. Measuring growth and growth inhibition based on mCherry detection 
The technical developments of the protocol had an impact on the sensitivity of the 
fluorescent intensity measurements. When cell numbers of Mes-Sa mCherry and the 2 
Dx5 mCherry lines were correlated to the measured intensity, better linearity was 
achieved with the well area scan mode (Figure 21/A; B; C). In every case, especially for 
Mes-Sa mCh, the coefficient of determination (R2) was better for well area scan mode. 
For the low mCherry expressing Dx5 cells, the correlation was good only above 20 000 
cells, which limits its usability in cytotoxicity measurements. 
As the cell number correlated well with fluorescent intensity, we measured both growth 
and growth inhibition of the mCherry expressing cells, but we used now only the well 
area scan mode with 5x250 flashes. The daily mCherry measurements to acquire growth 
curves were performed for all the 3 mCherry expressing uterine sarcoma cell lines for 
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Figure 21. Correlation of the cell number to the measured fluorescent intensity and the coefficient 
of determination (R-squared) for A) Mes-Sa mCherry for B) highly fluorescent Dx5 mCherry and 
for C) faint Dx5 mCherry expressing low level of fluorescent protein. 1000, 1250 and 5x250 



































































continuously increasing, while the plate reader could not detect the faint Dx5 mCh cell 
line reliably before 72 h (Figure 22/A). (Assuming one cell division per day, cell number 
exceeded 20 000 cells/well only after 48 h incubation time, which is in concordance with 
the correlation shown in Figure 21/C). Therefore the faint Dx5 cell line with low amount 
of mCherry was excluded from further experiments due to our inability to follow its full 
growth kinetics. To compare the growth rate of mCherry positive cells to their non-
fluorescent counterparts, we followed the growth also by the PrestoBlue viability reagent 
(Figure 22/B). For this purpose we used identically seeded plates, and each were assayed 
at a different day to obtain the growth curves. The proliferation of the cells were not 
affected by the mCherry expression, as fluorescent cell lines had identical growth rates to 
the ‘colorless’ cells. The PrestoBlue assay procedure we used was optimized for 72 h 
assays, and accordingly, the conversion of PrestoBlue to a highly fluorescent substrate 
during the 1 h incubation time saturated between 72-96 h. 
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Figure 22. Following cell growth A) with the fluorescent protein based assay of mCherry 
expressing Mes-Sa and two Dx5 cell lines with a well area scan protocol (5x250 flashes); B) with 





To investigate growth inhibition, we used both non-fluorescent and mCherry expressing 
cell lines, and we measured the cytotoxicity based on the fluorescent protein intensity, 
and also by PrestoBlue viability reagent. As test compound, we used the MDR-selective 
NSC693871 [98]. When after 72 h drug incubation we measured the mCherry intensity 
of the cells, we observed the MDR-selective behavior of the NSC693871 (Figure 23/A). 
The same plate was then assayed with PrestoBlue, and compared to another plate, where 
the same drug dilution was performed against non-fluorescent cells. The fitted dose-
response curves were almost identical of the non-fluorescent cells to their fluorescent 
versions (Figure 23/B). 











































Figure 23. Cytotoxicity of NSC693871 measured after 72 h incubation A) by PrestoBlue and B) 
by fluorescent protein based assay (well area scan mode with 5x250 flashes). 
Based on these result we concluded that the mCherry expressing uterine sarcoma cell 
lines fulfilled the criteria of being utilized in cytotoxicity (growth inhibition) 
determination of test compounds. Thus, we successfully optimized the mCherry based 
cytotoxicity measurements performed on 96 well plates. 
4.1.3.8. Robustness of 96 well plate fluorescent assays of mCherry expressing cells 
The 3 EnSpire protocol variants with 1000, 1250 or 5x250 flash numbers were 
consecutively developed for Mes-Sa mCh and Dx5 mCh cell mass measurements, which 
was based on the continuous checking of the assay robustness via the Z’-factor. Moreover, 
the 5x250 well area scan protocol was used twice to measure each plate: first after 72 h 
and then after 144 h drug incubation. As it is apparent from Figure 24 and Table 4, 
average Z’-factors were remarkably increasing due to the optimization steps. When 1000 




for both cell lines, but interplate differences were extremely high (Z’-factors were ranging 
from - 0.5 to 0.84), producing many uninterpretable experiments, which needed to be 
repeated. Increasing the flash number, the number of scanning points and the incubation 
time all improved our fluorescent protein based cytotoxicity assay (Figure 24). 
 
Figure 24. Individual Z’-factor values for the fluorescent protein based assay measuring 
mCherry. Single point detection (1000 and 1250 flashes) and well area scan (5x250 flashes) are 
plotted under the headings. Red line stands for the threshold of acceptable data, green line 
represents the preferable threshold of screening window coefficient for dose-response 
measurements (confirmatory and secondary steps). Tests were carried out on 96-well plates. 
Table 5. Average and standard deviation of Z’-factors calculated from the fluorescent 
protein based measurement performed on 96-well plates. 
Incubation time Flash no. Mes-Sa mCh Dx5 mCh  Usability 
72 h 
1000 0.23 ± 0.33 0.35 ± 0.31  - 
1250 0.40 ± 0.30 0.46 ± 0.19  primary 
5x250 0.68 ± 0.18 0.67 ± 0.16  primary, (confirmatory) 
144h 5x250 0.77 ± 0.20 0.75 ± 0.08  primary, confirmatory 
 
The protocol with 1000 flash no. would not be suitable for a cytotoxicity measurement, 
as too many assay plates returned a Z’-factor below zero. However, a 25 % increase in 
measurement time (to 1250 flashes) seems to be already suitable for primary screening, 
as only a few individual measurements has failed to reach the acceptable level of 




























well, beyond an excellent yes/no type assay measurement, dose response acquisition 
became available. To perform the confirmatory screening with the fluorescent protein 
based assay on 96-well plates, 72 h measurement is reasonably reliable, but 144 h 
measurement is preferred, as Z’-factors keep increasing with longer incubation time, 
exceeding the threshold of 0.5 more securely. 
As a conclusion of the optimization steps, we learned that 2D spatial distribution of the 
cells can influence the accuracy of fluorescent protein based assay immensely. As wells 
on the side of the microplate had more pronounced uneven distribution, it is 
recommended to avoid using them. Other factors such as the sensitivity of instruments 
(e.g. the sensitivity of the plate reader at certain wavelengths) or liquid handling accuracy 
can influence the robustness also. 
4.1.3.9. Scale down of the cytotoxicity assay volume to increase compound 
screening throughput 
We designed, optimized and successfully automated the fluorescent protein based 
cytotoxicity assay for 96 well plates, which was followed by primary and confirmatory 
compound screening of a small compound library (for the statistical characterization of 
the assay in 4.1.3.8, we used the control wells of the plates from the experiments presented 
later in point 4.3.4). In order to increase the assay throughput to screen larger compound 
libraries, we implemented the miniaturization of the cytotoxicity assay for 384 well 
plates. Preliminary experiments during optimization was carried out by using the 
mCherry expressing Mes-Sa cell line. 
Learning from the previous optimization procedure, we checked firstly the 2D 
distribution of cells. The wells on a 384 well plate have a different geometry: in contrast 
to the circular wells of a 96 well plate, wells of the 384 well plate are square shaped with 
rounded corners. Not surprisingly, also on the 384 well plates cells tend to migrate and 
grow close to the wall of the wells after attachment. We observed also intraplate 
differences. Cells in wells that are in the middle of the plate proliferated by the well’s 
wall in equal distribution (the gradient of cell mass was increasing to every direction from 
the middle of the well equally), while cells that were seeded in a side well (that is by the 
edge of a plate) migrated more likely to that wall or corner of the well, which is not in 




unpopulated in every part of the plate, we set a 4 point scanning protocol (4x250 flashes) 
with 1.75 mm distance between the points, where the highest cell density was expected 





Figure 25. A) Mes-Sa mCherry cells with various initial cell no. imaged by a fluorescent 
microscope after 72 h incubation. Red, green and blue rectangles refer to the intraplate position 
of the imaged wells. Effect refers to the observed gradient of cell mass. B) Heat map of Mes-Sa 
mCherry cells in the 4 corner wells (marked with blue in panel A), scanned and visualized by the 




In the next step, we optimized the initial cell number. Theoretically, the optimal initial 
cell number for Mes-Sa mCherry would be 1250 cells/well, as the area of one well on the 
384 well plate is approx. ¼ of the area of a well on a 96 well plate, where we seeded 5000 
cells/well. Thus, we examined the growth characteristic of 3 different initial cell numbers, 
625-, 1250-, and 2500 cells/well. When half amount of the expected initial cell number 
was seeded (625 cells/well), the confluency of the well after 120 h was still very poor, 
that is apparent also from the RFU values (Figure 26/A). Interestingly, when 1250 
cells/well were seeded, cell density was still not sufficient, as seen at 72 h, and the growth 
did not start to saturate until 120 h. The 2500 cells/well setting returned a better 
confluency after 72 h, and we observed that the growth followed the well-known logistic 
equation. 
For the initial cell number optimization, cells were seeded and followed in 60 μl of 
medium. We investigated also, if the change in the final volume is influencing cell 
growth. Thus, we designed a plate layout, where 2500 cells/well (Mes-Sa mCherry) were 
kept in 40-, 60-, or 80 μl of medium. By following cell growth for 120 h, we didn’t notice 
any difference in the proliferation rates (Figure 26/B). For practical reasons, we decided 
to keep using the 60 μl of final volume. 
However, what we observed during these preliminary experiments was the non-negligible 
effect of the evaporation of medium from the 384 well plate, especially from the outer 
rows and columns of wells, which was visible also by eye. Thus, we compared cell growth 
also by dividing the microplate into 3 parts: (1) the outer wells, which are on the edge of 
the plate, (2) the wells in the second rows/columns and (3) inner wells (the rectangle 
defined by the wells C3-N3-C22-N22). The growth rate was influenced by the extent of 
evaporation, as both the outer and the second row/column wells suffered variable levels 
of decrease in growth rates compared to the inner wells (Figure 26/C). As both medium 
evaporation and uneven distribution of the cells were more prominent in the outer wells, 
we excluded the outer and second line wells from further experiments, in favor of smaller 
interplate differences, and better assay robustness. However, as a positive control (dead 








Figure 26. Growth kinetics of Mes-Sa mCherry cell line under different conditions in 384 well 
(‘w’) plates. A) Influence of the initial cell number to cell growth kinetics. B) Cell growth in 
different volumes of medium. C) Effect of the evaporation of medium to the growth. 



















































After cell growth measurements, we followed the same logic as earlier, and checked the 
growth inhibition of the test compound NSC693871. The growth inhibition was followed 
daily for 144 h. At each day, the fluorescent intensity values were normalized to the 




Figure 27. Cytotoxicity of a test compound (NSC693871) against Mes-Sa mCherry on a 384 well 
plate, measured daily for 144 h. GI50 values (in μM) were obtained based on sigmoidal curve 
fitting, standard deviations (sd) were calculated from 8 parallel experiments. 
As a conclusion, we were able to demonstrate the dose-dependent cytotoxicity of 
NSC693871, thus mCherry fluorescence based assay was successfully optimized for 384 
well plates. 
4.1.3.10. Robustnes of the fluorescent protein based assay on 384 well plates 
In contrast to 96 well plate experiments, where compound testing was performed in 
packages concurrently to the optimization of mCherry detection (via flash number 
adjustments), screening of compound libraries on 384 well plates was carried out always 
with the same scan mode and measuring time. Thus, we examined only the incubation 
time dependence of the robustness. Despite the miniaturization, Z’-factor values remained 
acceptable (Figure 28). Measurements after 72 h incubation time returned a few 
individual vales below zero for Dx5 mCherry cells, while at 96 h and 144 h most of the 
values exceeded even the Z’-factor of 0.5. When the robustness of Mes-Sa mCherry 
experiments were quantified, all individual Z’-factors were above zero, regardless of the 
drug incubation time. Moreover, at 144 h, all the individual values calculated from Mes-
Sa mCherry fluorescence intensity were above 0.5. 
 GI50 sd 
24h 4.92 0.72 
48h 3.59 0.40 
72h 2.64 0.12 
96h 2.18 0.08 
120h 2.35 0.12 
144h 2.29 0.11 

























Figure 28. Individual Z’-factors calculated from the positive and negative control wells of the 
measured 384 well plates. Red line stands for the threshold of acceptable data, green line 
represents the preferable threshold of screening window coefficient for dose-response 
measurements (confirmatory and secondary steps); mCherry measurement was carried out by a 
well area scan protocol with 4x250 flashes. Data was obtained from the same plates at the different 
time points. 
For primary screening, the toxicity against Mes-Sa mCherry cells can be measured 
already after 72 h, while for Dx5 mCherry cells, growth inhibitory data is better to be 
measured only after 96 h incubation time. For dose-dependent cytotoxicity data, 144 h 
incubation time is preferred prior to detection for both cell lines. Average Z’-factor values 
for 72-, 96-, and 144 h measurements with the corresponding standard deviations are 
compiled in Table 6. 
Table 6. Average Z’-factors from 384w plates, and the possible usability of the assay. 
Incubation time Mes-Sa mCh Dx5 mCh  Usability 
72 h 0.43 ± 0.18 0.32 ± 0.29  (primary) 
96 h 0.64 ± 0.09 0.57 ± 0.09  primary, (confirmatory) 
144 h 0.75 ± 0.08 0.70 ± 0.10  primary, confirmatory 
 
4.1.3.11. Probing other fluorescent proteins in the cytotoxicity assay 
In a set of experiments (not included in this thesis), we measured cytotoxicity data against 
3 fluorescent cell lines. Each cell line expressed a different fluorescent protein in their 





















fluorescence strongly depends on the level of the fluorescent proteins in the cytoplasm, 
although other factors also play an important role. Such factors are the brightness and 
quantum yield of the fluorescent proteins. The quantum yield (QY) indicates the 
proportion of the energy that is emitted by the fluorophore after absorption. Brightness is 
the product of QY and the molar extinction coefficient, where the coefficient is defined 
as the quantity of light (at a given wavelength) that can be absorbed. Additionally, 
excitation energy is also a determinant factor of the fluorescence detection. Albeit the 
lamp power is not adjustable for the measurements with the EnSpire reader, due to an 
unfortunate event, the xenon flash broke, and had to be replaced. The new lamp performed 
with higher energy, whereupon the Z’-factor values of mCherry detections changed, and 
dose-response acquisition became available already after 72 h incubation (Table 7). The 
Z’-factors of mOrange and eGFP measurements were also considerably above 0.5 at each 
measured time point, thus were suitable for confirmatory screening of compounds.  
Table 7. Z’-factors of the fluorescent protein based assays after 72-, 96-, and 144 h drug 
incubation time. Flash no. refers to the measurement time in the well area scan mode. 
Brightness and QY (quantum yield) are quality metrics of the fluorescent proteins, and 
were taken from [145] [146] [147]. 
 Cell line    Mes-Sa Mes-Sa B1 Dx5  
 Fluorescent protein   mCherry mOrange eGFP  
 Flash no.    4x250  4x200  4x100 
 Brightness    15.8  34.8  33.6 
 QY     0.22  0.6  0.6 
 Z’-fact. at 72h   0.69 ± 0.12 0.72 ± 0.12 0.75 ± 0.11 
   96h   0.78 ± 0.11 0.78 ± 0.11 0.84 ± 0.11 
   144h   0.85 ± 0.09 0.77 ± 0.12 0.87 ± 0.10 
As a summary of the results introduced in 4.1, we were able to adapt a fluorescent protein 
based cytotoxicity assay, which is based on the linear correlation of the cell number and 
the measured fluorescent intensity. We successfully involved various cell lines with 
different fluorescent protein expressions, and investigated the impact of mCherry 




line. The cytotoxicity assay was automated for both 96 and 384 well plates, and the 
primary and confirmatory steps from the 3 step screening algorithm was designed to rely 
on this assay type. As a main conclusion of the optimization of the fluorescent protein 
based assay, we learned the importance to follow assay robustness via the Z’-factor during 
the series of experiments. As demonstrated, the robustness of the cytotoxicity assay is the 
function of the 2D distribution of the cells, the incubation time and the duration of 
measurements (flash no.), which all need to be considered and set before actual compound 
screening campaigns start.  
4.2. Identification and validation of MDR-selective compounds 
As a major aim (objective #2 and #3), we wanted to increase the number and the potency 
of MDR-selective compounds. To reach the goals, our strategy required the identification 
of chemotypes, which are associated to MDR-selectivity, and which can be the basis of 
focused library design, assembled by structural congeners. 
As the introduction/development of the fluorescent protein based assay and the 
implementation of the screening system went in parallel to cytotoxicity testing, several 
experiments, conducted in an earlier phase, were performed only manually, and in some 
cases, non-fluorescent cell lines were used predominantly. These experiments can be 
considered as secondary screening without prior primary or confirmatory steps. 
4.2.1. Delineating cell line specificity of compounds reported to show collateral 
sensitivity 
Our #2A objective was to catalogue, test and verify the MDR-selective toxicity of several 
reported substances, and identify the structures, which are associated to robust P-gp 
potentiated hypertoxicity. Therefore, we compiled a diverse cell line panel to probe these 
putative MDR-selective agents that were reported to kill P-gp overexpressing cancer cells 
in a preferential manner. The cell line set was comprised of two drug selected lines, the 
vinblastine treated KB-V1 cell line and the doxorubicin resistant Dx5 with their parental 
counterparts KB-3-1 and Mes-Sa, respectively. KB-3-1- and its P-gp expressing resistant 
derivatives were commonly used in studies dealing with collateral sensitivity in cancer 
(see in 1.3.2 and in 1.3.3), while Mes-Sa and Dx5 constitute a good model cell line pair 
to investigate MDR modulations [148]. Thus, the contribution of functional P-gp to the 
provoked hypertoxicity was investigated also by using Mes-Sa and Dx5 cells, when 




Additionally, we used an MDCK II cell line transfected with human P-gp to determine, 
if the transporter expression itself is sufficient to convey the hypertoxic effect compared 
to the parental MDCK II. The list of the compounds that we tested and their respective 
IC50 values are listed in Table 8 and Table 9. Average selectivity ratios (SR, IC50 parental / 
IC50 MDR) are also shown in the tables. 
Table 8. Cytotoxicity (IC50 in µM) against KB-3-1, KB-V1 and MDCK II cell lines of 
compounds that were identified previously to elicit collateral sensitivity. Viability was 
assessed by PrestoBlue reagent. *, P < 0.05; **, P < 0.01. SR stands for selectivity ratio; 
TEDB is the abbreviation of 6,8,8-triethyldesmosdumotin B. 
Compound KB-3-1 KB-V1 SR  MDCK II MDCK II B1 SR 
Verapamil 55.2 69.5 0.8  52.6 43.6 1.2 
Reversin121 >>150 >>150 -  >>150 >>150 - 
TritonX-100 55.4 47.8 1.2  73.7 97.6 0.8 
TEDB 198 100 2.0**  >>200 >>200 - 
4’-Me-TEDB 26.4 14.6 2.1*  97.4 96.6 1.0 
4’-Et-TEDB 13.0 7.7 1.7*  >>200 >200 - 
Pluronic P85 126 129 1.0  80.7 93.4 0.9 
Dp44mT 0.071 0.055 1.4  0.0035 0.0026 1.3 
Rotenone 0.136 0.136 1.1  0.150 0.115 1.4 
KP772 64.0 12.2 7.0**  6.6 4.0 1.6* 
 
Table 9. Cytotoxicity (IC50 in µM) against Mes-Sa and Dx5 cell lines of compounds that 
were identified previously to elicit collateral sensitivity. Viability was assessed by 
PrestoBlue reagent. (i): P-gp inhibitor tariquidar (t) or PSC833 (p).*, P < 0.05; **, P < 
0.01. SR stands for selectivity ratio; TEDB is the abbreviation of 6,8,8-
triethyldesmosdumotin B. 
Compound Mes-Sa Dx5 SR  Mes-Sa (i) Dx5 (i) SR (i) 
Verapamil 49.4 33.2 1.5**  30.2 17.7 1.7**
 (t) 
Reversin121 131.0 13.0 10.8**  95.4 12.3 7.6**
(t) 
TritonX-100 29.9 9.3 3.4**  24.2 9.9 2.6*
(p) 
TEDB 91.7 67.2 1.4  - - - 
4’-Me-TEDB 36.3 29.1 1.3  - - - 
4’-Et-TEDB 41.5 19.9 1.9  - - - 
Pluronic P85 45.9 49.1 1.0  - - - 
Dp44mT 0.045 0.019 2.7*  0.046 0.010 4.8**
(p) 
Rotenone 0.090 0.078 1.2  - - - 





Pluronic P85 and rotenone, the two compounds that were reported to act selectively on 
the mitochondrial electron transport chain of MDR cells [80] [88] were equally toxic to 
all parental – MDR pairs. Verapamil, reversin121 and TritonX-100 were selectively toxic 
only to the Dx5 cell line, moreover this selectivity remained significant when the function 
of P-gp was blocked by inhibitors. Interestingly, these 3 agents were all reported to 
interact with P-gp by stimulating its ATPase activity in low (non-toxic) concentrations, 
and inhibiting the transport activity at higher doses [80] [82] [83]. We have found that the 
compounds Dp44mT and the desmosdumotin B analogues also possessed cell line 
specific activity in the panel we used. Dp44mT was not hypertoxic to KB-V1 cell line, 
which contradicts the literature data [103], and its selective toxicity to Dx5 cells has 
increased rather than decreased in the presence of TQ. Desmosdumotins, proposed to 
confer an extreme level of collateral sensitivity due to special cellular changes acquired 
in response to vincristine selection [84] exerted a slight but preferential toxicity only to 
the vinblastine selected cell line KB-V1. Only KP772, the compound that was identified 
by Heffeter et al. [104] and also later by the systematic study of Türk et al. [98] has shown 
hypertoxicity against MDR cells in the entire panel, which was P-gp-dependent, as its 
selective manner has vanquished in the presence of a P-gp inhibitor. 
The results were unexpected, especially in the case of Dp44mT and desmosdumotins, 
which prompted us to investigate their selective toxicity in an extended cell line panel. 
4.2.1.1. Results of the additional experiments with the thiosemicarbazone Dp44mT 
In the cell panel we used for the verification of drugs having robust P-gp-mediated MDR-
selectivity we included additional in vitro MDR models: the retrovirally transduced A431 
and A431-B1 cells, and a cell line expressing high levels of endogenous P-gp (HCT-15), 
which was tested against Dp44mT also in the presence of tariquidar (Figure 29/A). 
Regrettably, we failed to confirm the P-gp-dependent MDR-selective toxicity of Dp44mT 
also with the extended panel. The collateral sensitivity that KB-V1 cells shown to 
Dp44mT was reported to happen through a P-gp-mediated lysosomal accumulation of the 
copper complex of Dp44mT, which harbors redox-activity, leading to lysosomal-
membrane permeabilization and apoptosis [149]. However, as demonstrated in the 
literature [150], P-gp is localized primarily in the plasma membrane, and absent in the 
lysosomes (unless being degraded). Accordingly, when we stained the lysosomes and the 




lack of lysosomal P-gp in our cell line (and presumably in all of our MDR lines) explains 
why we could not reproduce the published results. Irreproducibility was probably due to 
the different way of vinblastine (VBL) selection of KB-V1 lines, as we used 300 nM VBL 
prior to the experiments, while Richardson and co-workers used 1000 nM VBL 
concentration [103], which resulted in such an extreme P-gp overexpression, that it 




Figure 29. Additional experiments in relation with Dp44mT. A) Cytotoxicity of Dp44mT against 
additional cell lines. B) Confocal microscopy image of KB-V1 cells to determine the subcellular 
localization of P-gp (marked with the antibody MRK16, green), lysosomes (LAMP1, red) and 
nuclei (DAPI, blue). Scale bar, 10 µM. Figures were taken from [151]. 
4.2.1.2. Results of the additional experiments with the flavonoid desmosdumotin B 
analogues 
In the case of desmosdumotins, additional cell lines were also involved to assess the 















































the selective manner of desmosdumotins, namely KB and the vincristine selected KB-
VIN (Table 10). We used also the fluorescent OVC-8 and its resistant phenotype, the 
doxorubicin resistant NCI/ADR-RES cell line pair to test desmosdumotins (Table 11). 
Table 10. IC50 values (in μM) of vincristine (VCR) and desmosdumotin B analogues 
against KB and KB-VIN cells measured by SRB assay. SR: selectivity ratio, RR: 
resistance ratio. ** P < 0.01; ns: not significant. (I) refers to P-gp inhibitor tariquidar or 
verapamil. TEDB: 6,8,8-triethyldesmosdumotin B. 













TEDB >236 1.07 >221  -   391 230 1.7ns - 211 1.9ns - 
4'-Met-
TEDB 
39.2 0.08 460 - 
 23.1 10.5 2.2
ns - 11.5 2.0ns - 
4'-Et-
TEDB 
21.9 0.07 320 - 
 18.2 7.75 2.3** - 6.4 2.9** - 
VCR 0.018 8.5 -  467   0.004 0.57 -  128** 0.003  - 0.7
ns 
 
The cytotoxicity of the 3 desmosdumotin analogues showed a selective tendency against 
KB-VIN cells, although significant selectivity was observed only in the case of 4’-Et-
TEDB. Nevertheless, the selectivity ratio was much lower than expected based on the 
available literature data, moreover the selective manner was not sensitive to P-gp 
inhibition. Furthermore, the MDR cell line NCI/ADR-RES has tolerated the toxicity of 
desmosdumotin flavonoids significantly better than the parental OVC-8 (Table 11), 
resistance was approx. 2-fold, further indicating that P-gp was not inducing a general 
sensitivity when desmosdumotins were applied. 
Table 11. IC50 values of vinblastine (VBL) and desmosdumotin B analogues against 
OVC-8 DsRed2 and NCI/ADR-RES eGFP cells measured by the fluorescent protein 
based assay. *P < 0.05; **P < 0.01. 





TEDB [µM] 15.6 36.1  0.4** - 
4'-Me-TEDB [µM] 3.86 6.75 0.6* - 
4'-Et-TEDB [µM] 1.86 3.4 0.5* - 




Based on the results, it is clear that the function of P-gp cannot exclusively account for 
the collateral sensitivity of MDR cells to desmosdumotin B analogues. In our hands, only 
the vinca-alkaloid resistant cells lines (KB-V1 and KB-VIN) were killed preferentially, 
but the effect was marginal, and was not abolished by P-gp inhibitors. 
By testing the compounds reported in the literature to provoke collateral sensitivity, our 
aim was to identify potent MDR-selective structures, which could be further optimized 
by testing their congeners. Strikingly, the majority of the data published in the literature 
could not be reproduced. With the exception of the 1,10-phenanthroline - metal complex 
KP772, none of the compounds exerted a robust MDR-selective toxicity, showing 
increased potency only in a subset of selected MDR cells.  
4.2.2. Identification of MDR-selective compounds from the DTP drug repository 
In search for additional MDR-selective candidate molecules we intended to repeat the in 
silico data mining followed by in vitro cytotoxicity validation from the NCI DTP drug 
repository database. This aim (objective #2B) was based on the good hit validation ratio 
of a former systematic analysis by our research group [98], when several previously 
unknown MDR-selective agents were identified from a former (shorter) version of the 
database. 
The DTP’s database in 2010 contained the pGI50 values of 49169 compounds, which was 
a 13 % increase to 2007, when the previous data mining took place [98]. Due to the 
extension of the database (by retesting already existing entries and inserting new 
compounds), the number of missing data (NA) per compound had slightly decreased, in 
2007 there were 9.2 NA/compound, while in 2010 it was reduced to 7.8 NA/compound 
(from the maximum of 60 data). By performing the Pearson’s correlation, 224 hits 
returned a strong positive association between drug activity and (mRNA)MDR1 level (rp 
> 0.4). The consecutive filters (see algorithm in 3.1.), that removed hits with unreliable 
correlation coefficient reduced the number of candidate compounds to 80, of which 61 
compounds were already identified and published from the data mining from the release 
of 2007. Of the 19 newly identified in silico hits, only 14 were made available by DTP, 
and we could purchase an additional hit from commercial sources. There were 4 
remaining compounds, that neither DTP nor vendors could provide to us, thus were 





4.2.2.1. Systematic in vitro cytotoxicity testing of the newly identified MDR-
selective candidates 
To characterize the in vitro cytotoxicity profile of the available, newly identified in silico 
hits, we used the same compilation of cell line pairs, which we used for characterizing 
the collateral sensitivity of reported substances (see 4.2.1), as it proved to be a useful cell 
panel in the validation of MDR-selectivity. As we already had approximate pGI50 values 
for each compounds from the database, no primary screening experiments were 
necessary. Cytotoxicity was assessed either by the conventional MTT assay or by 
PrestoBlue assay. Additionally, it was the first time that we applied the fluorescent protein 
based cytotoxicity measurements with OVC-8 DsRed2 and NCI/ADR-RES eGFP cell 
lines to test a compound set (and the usability of this novel kind of assay at the same 
time). 
Not available compounds (NSC609800, NSC748494, NSC726708 and NSC740464) 
were excluded from the following cytotoxicity tables (Table 12-13-14). NSC716771 was 
also not available, results for KB-3-1 and KB-V1 cell lines – measured by MTT assay – 
were taken from [100], and were inserted to Table 13. The compounds NSC627452 and 
NSC733435 did not show cytotoxic effect (up to 100 μM) to any of the cell lines, thus 
they do not appear in the tables either. The obtained MDR-selective candidate compound 
set was supplemented with the control compounds NSC73306 and NSC693871, which 
were reported earlier [98].  
Results against OVC-8 DsRed2 and NCI/ADR-RES eGFP cell lines, performed with 
manual pipetting on 96 well plates, are shown in Table 12. NSC79544 had a strong 
fluorescence, which interfered with both DsRed2 and eGFP measurements, thus we were 
unable to detect its cell growth inhibitory potential. The control compounds NSC73306 
and NSC693871 were significantly more toxic to the MDR phenotype both at 72 h and at 
144 h, as expected. Of the newly returned hit compounds (hits from the 2010R but not 
from the 2007R), a greater part (7 compounds) was selectively toxic to the MDR-subline 
NCI/ADR-RES eGFP both after 72 h and after 144 h incubation time. Four compounds 
killed the MDR cell line preferentially with a significant selectivity only at 144 h but not 
at 72 h. There was only one compound (NSC67090) that was not significantly more toxic 




Table 12. Half maximal growth inhibition values (GI50 in μM) and selectivity ratios (SR) 
measured against OVC-8 DsRed2 and NCI/ADR-RES eGFP cells at 72 h and at 144 h. 
All values were derived from at least 3 independent experiments. SRs were significant if 
the GI50 values between the cell lines were significantly different (unpaired t-test; 
P < 0.05:*; P < 0.01:**). The NSC substances in bold are previously identified, robust 
MDR-selective compounds. 











NSC15372 38.1 9.9 3.8**  33.6 11.2 3.0** 
NSC72881 3.1 2.4 1.3  6.3 3.7 1.7** 
NSC297366 1.7 0.4 4.4**  1.5 0.2 8.2** 
NSC1014 7.9 3.8 2.1**  8.7 3.5 2.5** 
NSC57969 3.7 0.9 4.0**  4.2 0.6 6.7** 
NSC693871 8.3 2.6 3.2**  9.8 1.9 5.3** 
NSC48892 1.3 0.7 1.8*  1.2 0.7 1.7* 
NSC79544 Fluorescent compound  Fluorescent compound 
NSC67090 1.9 1.5 1.2  1.9 1.0 1.9 
NSC676735 4.2 1.8 2.3  2.9 1.2 2.4* 
NSC608465 2.0 1.3 1.5**  2.6 0.9 2.8** 
NSC13977 5.2 3.5 1.5**  5.7 2.7 2.1* 
NSC672035 88.5 69.8 1.3  90.8 37.4 2.4** 
NSC73306 4.6 2.5 1.8**  5.6 2.2 2.6** 
NSC17551 9.2 5.9 1.6   9.8 3.4 2.8** 
 
We used the MTT assay to measure cytotoxicity against KB-3-1 and KB-V1 cell lines, 
and when compounds were tested against MDCK II and MDCK II B1 cell lines. Results 
are presented in Table 13. The control compounds NSC73306 and NSC693871 exerted 
hypertoxicity against the MDR cell lines as expected, as so 7 of the hit compounds. All 
of these MDR-selective compounds were selectively toxic also to NCI/ADR-RES eGFP 
cell line. Cell line specific MDR-selectivity was also observed, NSC79544 killed only 
KB-V1 preferably, but not MDCK II B1. On the other hand, compounds NSC1014 and 
NSC67090 showed only MDCK II B1 selectivity. Three compounds (NSC15372, 
NSC72881, NSC672035) were equally toxic to KB and to MDCK cell lines, when 





Table 13. Results of MTT assay (IC50 in μM and selectivity ratio-SR) of the MDR-
selective candidates. Data for NSC716771 were taken from [100]. NSC compounds in 
bold are known MDR-selective, control agents. SRs are significant if the difference 
between the IC50 values are significant (unpaired t-test, P < 0.05:*; P < 0.01:**). 
NSC code KB-3-1 KB-V1 SR  MDCK II MDCK II B1 SR 
NSC15372 12.8 13.5 0.9  40.3 38.0 1.1 
NSC72881 15.8 10.2 1.5  18.1 13.5 1.3 
NSC297366 2.1 0.1 16.4**  2.8 0.3 10.0** 
NSC1014 5.8 4.3 1.3  10.8 5.6 1.9** 
NSC57969 8.6 0.6 14.4*  4.4 0.8 5.5** 
NSC693871 13.6 2.1 6.6**  14.5 2.9 4.9** 
NSC48892 3.2 1.9 1.7**  3.6 2.3 1.6** 
NSC79544 2.2 0.7 3.0**  1.3 1.0 1.2 
NSC67090 3.8 2.8 1.4  3.8 1.8 2.2** 
NSC676735 7.2 3.4 2.1*  12.9 9.2 1.4** 
NSC608465 2.6 1.0 2.5*  2.5 1.3 2.0* 
NSC13977 10.5 4.3 2.4**  9.1 4.4 2.1** 
NSC672035 67.7 56.8 1.2  31.4 54 0.6 
NSC73306 7.5 3.7 2.2**  6.7 2.8 2.4** 
NSC17551 8.7 4.5 1.9**  14.4 4.5 3.2** 
NSC716771 13.1 5.8 2.3         
 
We tested the newly identified candidates also against Mes-Sa and Dx5 cell lines, using 
PrestoBlue viability reagent. To assess the contribution of functional P-glycoprotein to 
MDR-selectivity, we performed the experiments in the presence/absence of the 3rd 
generation P-gp inhibitor tariquidar (TQ). Results are presented in Table 14. The control 
compounds NSC73306 and NSC693871 were hypertoxic to the MDR cell line Dx5, and 
this toxicity decreased significantly, when drugs were co-incubated with TQ. 6 of the 7 
compounds that conferred selective toxicity to the other 3 MDR cell lines (NCI/ADR-
RES, KB-V1, MDCK II B1) were more toxic to Dx5 cells as well compared to its parental 
from. Moreover, all of these compounds lost (at least partly) their ability to kill MDR 
cells preferably when TQ was present and inhibited the function of ABCB1. NSC48892, 
the 7th compound, had a selectivity of 1.8 against the Dx5 cell line, which was just not 
significant at P < 0.05 (its probability value was 0.062 calculated from 3 independent 
experiments), although SR decreased to 1.3 in the presence of TQ. NSC72881 and 




act cell line specifically, as besides Dx5 it was hypertoxic only to NCI/ADR-RES eGFP 
cell line, with low selectivity. Interestingly, NSC67090 acted controversially, when TQ 
was present, its toxicity against Dx5 remained unaffected, while it became more toxic 
against Mes-Sa. Two candidates (NSC15372 and NSC672035) were equally toxic to 
Mes-Sa and Dx5 cells (thus were not tested in the presence of TQ). NSC1014 and 
NSC79544 had a slight but not significant selective toxicity against Dx5 cells. 
Table 14. Results of the in silico hits measured by PrestoBlue viability reagent. IC50 
values are presented in μM. The SRs were considered significant if the IC50 values were 
statistically different (unpaired t-test, P < 0.05:*; P < 0.01:**). TQ (tariquidar): 1 μM. 
 
 
By summarizing the in vitro cytotoxicity data, we could successfully verify the non-cell 
line specific MDR-selective toxicity of 6 candidates (NSC297366, NSC57969, 
NSC676735, NSC608465, NSC13977, NSC17551). All of these compounds lost their 
MDR-selective toxicity in the presence of TQ. The other 7 compounds were hypertoxic 
only to certain MDR cell lines (thus, there were no compounds that were not hypertoxic 
to at least one of the four MDR cell lines). The most prominent of the validated hits was 
the 8-hydroxy-quinoline (8-OH-Q) analogue NSC297366, which produced the highest 
selectivity ratios in every case.  
NSC code  Mes-Sa Dx5 SR  Mes-Sa(TQ) Dx5(TQ) SR(TQ) 
NSC15372  28.3 32.8 0.8  - -  
NSC72881  34.3 12.5 2.7**  31.4 29.7 1.1 
NSC297366  2.0 0.11 17.8**  1.6 1.5 1.1 
NSC1014  17.6 10.6 1.7  16.7 11.8 1.4 
NSC57969  4.4 0.6 7.6**  4.6 3.5 1.3 
NSC693871  4.9 1.3 3.9**  4.8 3.4 1.4 
NSC48892  3.6 2.0 1.8  3.7 2.7 1.3 
NSC79544  2.6 1.7 1.5  2.2 1.9 1.1 
NSC67090  3.6 1.3 2.8**  2.4 1.4 1.7 
NSC676735  19.5 6.1 3.2*  19.1 14.6 1.3 
NSC608465  3.4 1.1 3.0*  4.8 3.3 1.5 
NSC13977  7.9 3.0 2.6*  7.7 5.2 1.5 
NSC672035  51.9 53.6 1.0  - -  
NSC73306  6.8 2.9 2.3**  5.3 3.9 1.4* 




4.2.2.2. Investigation of the structural coherence of the MDR-selective compounds 
To characterize the structural coherence of the MDR-selective compounds identified from 
DTP database, we performed a 2D structural clustering. Compounds with a certain degree 
of similarity were then designated as chemotypes. Our goal with the structural clustering 
was to further confirm the already known MDR-selective chemotypes (from [98]), and to 
identify additional MDR-selective toxicity associated clusters (objective #2C). The 
defined chemotypes are useful to find more interesting molecules from the DTP 
repository or from other structural databases of APIs, which are available for purchase, 
leading potentially to preliminary SAR studies related to P-gp mediated hypertoxicity, as 
in [98].  Structural clustering was performed involving all the 19 hits that we identified 
from the DTP repository released in 2010. The clustering was supplemented with MDR-
selective control compounds, which derive also from the DTP database, but were 
identified and published earlier (Figure 30). The control compounds were NSC73306, 
NSC693871, NSC10580, NSC168468, NSC292408 and NSC713048, all of them were 
selectively effective against several P-gp expressing MDR cell lines [98].  
Figure 30. 2D Tanimoto Similarity of the 19 in silico hit compounds supplemented with MDR-
selective compounds identified earlier from the DTP database [98] [140]. Compounds in italics 
were not available, thus not tested in vitro. Underlined compounds were tested but were not active 
against any of the cell lines. Compounds in bold showed robust MDR-selectivity. Arrows indicate 
the chemotype of the molecules (in the case of 8-hydroxyquinolines, color of the arrows indicates 




The MDR-selective compound set, identified from the DTP database, is abundant in 8-
hydroxyquinoline (8-OH-Q) derivatives, there are six structures with this backbone. 8-
OH-Qs substituted at the 5-, or 2-positions (NSC79544 and NSC48892, NSC67090) 
showed moderate SR values. However, certain 8-OH-Qs substituted at the 7-position 
seem to have higher potency (both higher selectivity and toxicity). In contrast to the less 
potent NSC1014, which has a bulkier residue with two aromatic rings at the 7-position, 
both of the two best performing hit compounds NSC57969 and NSC297366 consist only 
1 ring at R7. Correspondingly, the control compound NSC693871 is structurally very 
similar to NSC57969, and it is also among the best performing MDR-selective molecules. 
The structure of NSC13977 (Alizarin Blue) contains a quinoidic system, and although it 
clustered separately, it resembles to a sulfonated 8-OH-Q condensed with an 
1,4-naphtoquinone. Structures of 8-OH-Qs and NSC13977 are shown in Figure 31. 
 
Figure 31. Structure and position numbering of the 8-OH-Q core. Structures of the 8-OH-Q 
derivatives are shown in the boxes according to the position of the residues (halogen atoms are 
not considered in this figure). NSC13977 is also sketched here, as it contains an 8-OH-Q 
substructure, where the aromaticity is disrupted, however with the additional connected aromatic 
ring system it resembles to NSC48892. 
The MDR-selective toxicity of the 1,10-phenanthroline (1,10-phen) and its metal 




completed the list of MDR-selective 1,10-phens with a tin and a palladium complex, the 
NSC608465 and NSC676735, respectively (Figure 32). The 1,10-phen hits we identified 
exert robust, although moderate collateral sensitivity against MDR-cells with the highest 
SR of only 3.2 (NSC676735 against Mes-Sa over Dx5, Table 14). 
 
Figure 32. MDR-selective 1,10-phen complexes. NSC292408 was identified from the DTP 
database released in 2007, while NSC608465 and NSC676735 were found in the subsequent data 
mining from the DTP release in 2010. 
NSC72881, a compound that seemed to show cell line specific collateral sensitivity was 
not clustered close to any compounds, although it resembles to the aryl-hydrazone 
tautomer NSC168468, which is a robust MDR-selective compound that was identified 
earlier (Figure 33/A). NSC17551 belongs to the group of ß-diketones, which chemotype 
was not associated to MDR-selectivity so far (Figure 33/B). The ß-isatin-
thiosemicarbazone NSC716771, which is a close analogue of NSC73306 was not 
available, but its MDR-selectivity is known from the literature [100] (Figure 33/C). 
A)    B)    C)  
Figure 33. Structures of the MDR-selective A) arylhydrazones (NSC168468, NSC72881), B) ß-




The 4 non-available compounds are structurally diverse. NSC740469 consists a 1,4-
naphtoquinone condensed to other aromatic rings, and a ß-diketone motif is also present 
in a tautomer form, which were present in the molecules NSC13977 and NSC17551, 
respectively. NSC748494, NSC726708 and the NSC609800 (which is similar to an 
isoflavone) are not related to the known chemotypes. Unfortunately, the putative MDR-
selective toxicity of the 4 non-available compounds remains unknown (Figure 34). 
 






Figure 34. Non-available compounds from the in silico screening, which were not closely related 
to any identified MDR-selective chemotypes. 
4.3. Screening of compound libraries focusing on flavonoid, TSC and 8-OH-
quinoline chemotypes to explore collateral sensitivity 
The establishment of the 3-step screening system created the possibility to test large 
amount of compounds. Based on the identified chemotypes, harboring distinct chemical 
features associated with MDR-selectivity, we compiled and purchased approx. 1800 
compounds from commercial sources representing all the chemotypes, and 336 further 
structural analogues from the DTP repository were also acquired. Our compound library 
was enriched with additional molecules that we obtained via collaborations. 
4.3.1. Primary screening of the compound collection 
The investigation of the compounds (thus chemotypes) was initiated with a primary 
screening. 2160 molecules were tested in 10 μM and in 100 μM concentrations against 




compounds were tested in 4 campaigns, firstly 756 molecules on 96 well plates, then 1404 
compounds on 384 well plates in 3 parts. 
Initially, when the first campaign was carried out, besides measuring the fluorescent 
signal of the surviving cells at 96 h, we obtained the fluorescent signal of the wells right 
after compound addition (which time point was considered as 0 h). This extra step served 
to identify inherently fluorescent molecules, as the outstanding emission of wells at this 
point could be addressed only to compound addition. As fluorescent molecules in the 
primary assay appeared as non-toxic compounds (high intensity refers to high amount of 
intact cells), this step was meant to reduce the number of false negatives. (Not shown here 
in details, but when fluorescent substances were re-tested with a counter assay, they 
possessed cytotoxic effect, e.g. NSC79544 was highly fluorescent, and was toxic to cells, 
which was revealed when MTT or PrestoBlue assays were applied, as shown in Tables 
12-13-14. Similarly to fluorescent substances, such light absorbing compounds, which 
decrease the fluorescent signal, are also capable to interfere with the fluorescent protein 
based assay. As lower fluorescent signal level refers to lower cell number, this effect 
could produce false positive hits. 
The 0 h fluorescent intensity measurement for the compounds, which were obtained from 
DTP and were tested in the primary screen on 96 well plates, are shown in Appendix 4. 
As in the 756 compound set, the number of fluorescent compounds was negligibly low, 
and we did not observe any initial decrease in the signal of mCherry, we stopped 
measuring fluorescence at 0 h, when we switched to 384 well plates, mostly to save the 
measurement time and the workload of the plate reader. (Moreover, perception of highly 
fluorescent compounds were possible also from the 96 h measurement data, as 
calculations returned impossibly high amount of cells). 
The 96 h growth inhibition effect of the compounds measured on 384 well plates are 
shown in Figure 35. 38% of the compounds exerted less than 50 % GI at 100 μM against 
both Mes-Sa mCh and Dx5 mCh cell lines, thus were considered not toxic (NT). 5% of 
the compounds were selectively toxic against the parental line in at least 1 concentration 
(putative P-gp substrates) and 14% were killing the MDR cells preferably (putative 
collateral sensitivity eliciting agents). Another 14% of the compounds were toxic to both 








Figure 35. Growth inhibition (GI) effect of 1404 molecules tested in the primary screen on 384 
well plates in A) 10 μM and in B) 100 μM drug concentrations. Each dot represents the percentage 
of GI exerted by a compound against a cell line. Blue dots (quasi blue line): GI values against 
Mes-Sa mCh cell line in ascending order, red dots: corresponding GI values against Dx5 mCh 
cell lines. 100 % refers to complete growth inhibition, thus effects of the most toxic substances 
are located in the top right corner of the graph. 
4.3.2. Utilization of the screening platform to identify improved MDR-selective 
compounds of the 8-OH-Q chemotype 
To find more potent MDR-selective agents, and to perform basic SAR studies within the 
designed chemical space, we intended to test the majority of the toxic compounds in a 
dose-dependent manner. The performed consecutive confirmatory and secondary 
screening is exemplified herein via the optimization of the 8-OH-Q compounds, to 
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vendors and from the DTP repository. In addition, we obtained compounds from two 
cooperating partners (Dr. Tibor Soós, MTA TTK; Dr. Ferenc Fülöp, SZTE) who 
synthesized analogues, which were not available from commercial sources. The 
congeners were designed of R2, R7 and R5 position substitutions (Figure 36). 
 
Figure 36. General formula of the compounds that are subject to the international patent 
application “MDR-reversing 8-hydroxy-quinoline derivatives”. The core structure of the 
chemotype is 8-OH-Q, when R2, R5 and R7 are hydrogen atoms. 
The confirmatory screening of 8-OH-Qs were conducted against the Mes-Sa mCh and 
Dx5 mCh cell lines on 384 well plates, where the molecules were tested in 9 concentration 
points. As apparent from Figure 37, there were compounds, which killed Dx5 preferably, 
but we found also molecules with equal toxicity to the parental and MDR cell lines, and 
potential P-gp substrates were also identified (some inactive compounds were designed 
on purpose to investigate the relevance of certain functionalities. 
 
Figure 37. Confirmatory screening result of the 8-OH-Q library measured by the fluorescent 
protein based cytotoxicity assay. Growth inhibition effects of the tested molecules are presented 
as GI50 values, and are shown in blue for Mes-Sa mCh, and the corresponding GI50s against Dx5 
mCh in red. Each point represents the average GI50 values of a compound, which were plotted in 
an ascending order based on the GI50 values against Mes-Sa mCherry. 
Those 8-OH-Qs, which showed a dose-dependent cytotoxicity (when GI50 values could 
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screening, where drugs were tested on 96 well plates manually, and viability was assessed 
with PrestoBlue viability reagent, which served as a counter assay. The results for the 
non-fluorescent Mes-Sa and Dx5 cells are shown in Figure 38/A. Many compounds that 
we acquired via the collaborations, as a result of designed synthesis, entered directly to 
this step of testing, as primary and confirmatory screens were performed in campaigns, 
while synthesized compounds arrived disorderly in time. To investigate if the selective 
toxicity against Dx5 cells was conferred by the P-gp function, we repeated those 
experiments in the presence of 1 μM TQ, where drugs were possessing a significant 





Figure 38. Cytotoxicity (IC50 in μM) of 8-OH-Qs against non-fluorescent Mes-Sa (blue) and Dx5 
(orange) cells measured by PrestoBlue viability reagent in the (A) absence and (B) presence of 
1 μM TQ, tested manually on 96 well plates. Each point represents the average IC50 value of a 
molecule, plotted in ascending order based on the IC50 values against the parental cell line. 
As apparent from Figure 38/B, the preferential toxicity of the most 8-OH-Q analogues 
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selective agents. In the terms of secondary screening, the robustness of the MDR-selective 
cytotoxicity of a subset of molecules were tested against additional parental-MDR cell 
lines pairs. Results against A431 & A431-B1, KB-3-1 & KB-V1 and MDCK II & MDCK 







Figure 39. Cytotoxicity (IC50 in μM) of selected subsets of 8-OH-Qs measured by PrestoBlue 
viability reagent against (A) A431 cell lines, (B) KB-3-1 and KB-V1 cell lines, (C) MDCK II cell 
lines. Each point represents the average IC50 value of a drug, and data points are plotted in an 
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Majority of the tested 8-OH-Q compound set elicited P-gp mediated MDR-selectivity 
against drug selected (Dx5, KB-V1) and against MDR1 transfected (A431-B1, MDCK II 
B1) cell lines. 
As a next step, we wanted to investigate, which structural modifications granted improved 
potency for our compounds during the optimization via designed synthesis. The 
comparison of only the selectivity ratios or the cytotoxicity would not give appropriate 
answer, as potency is the function of both. Thus, we introduced the activity index (AI) of 
the compounds as follows: 
AI = SR/IC50MDR. 
The activity index assigns MDR-selective potency to the tested drugs, which can be 
compared to each other to find the best performing entities against a resistant cell line.  
As cell lines have their inherent susceptibility towards xenobiotics in general, which 
might depend e.g. on their proliferation rate or on the mutations they harbor, we 
introduced also the normalized activity index (NAI), which characterizes the potency of 
MDR-selective agents in a way, that it is comparable between cell line pairs. The NAI 
was calculated as follows: 
NAI = (“individual AI” – “average AI of compound set”) / “sd of AIs of compound set”. 
As derived from the equation, NAI can be the basis to compare MDR-selective potency 
of drugs only when the same set of compounds were tested against all the cell lines in the 
investigation, as individual AIs are normalized to the statistics of the compound set 
(average and standard deviation of AIs), which would be distorted e.g. if for a cell line 
pair, only half of the compounds would be included in contrast to the other cell lines. If 
we include several other compounds in the set, the NAI will change for every compound. 
However, the interpretation of NAI remains the same. Drugs with a NAI of 0 are 
possessing the average potency in the set. Drugs with NAI < 0 are less potent, while drugs 
with NAI > 0 have a more pronounced MDR-selective effect compared to the average 
potency in the compound set. Thus, NAI can support the drug optimization by indicating 
possible cell line specific improvement of compounds, but most importantly we used it 


















Figure 40. Normalized activity index (NAI) of a subset of 8-OH-Qs tested against A431 and 
MDCK II cell lines, and against Mes-Sa & Dx5 cell lines. Compounds in the red and blue boxes 
belong to subclusters of 8-OH-Qs depicted above them. Compounds on the right (compound 33 
– 37) were identified through the systematic investigation of the DTP repository, of which the 
best performing NSC297366 is indicated, and followed by NSC57969, NSC48892, NSC693871 
and NSC693872 in this sequence. 
Based on NAI, the improvement of 8-OH-Qs through design and synthesis was 
successful, as NAI pattern was similar for all the 3 cell lines pairs. When analogues were 
tested against KB-3-1 and KB-V1, the NAI pattern was in concordance to the results 
shown in figure, but due to lack of data (only 60% of the compound subset was tested), 
we were not able to compare the potency against KB-V1 via NAI values properly. The 
successful optimization returned also slight differences between cell lines. Improvement 
against A431 cells was better when tetrahydro-isoquinoline moieties were present in R7, 
but against MDCK II cell lines and against Mes-Sa/Dx5 the methoxy-substituted benzil-
amine containing molecules were performing better. Nevertheless, the previously 
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returned a negative NAI, referring to “worse than average” MDR-selective effect among 
the investigated drugs. 
4.3.3 Screening and testing a TSC library against resistant cancer  
Thiosemicarbazones (TSCs) are known for their potential anticancer properties, 
moreover, certain TSC analogues are capable to provoke P-gp mediated MDR-selective 
cytotoxicity (see in 1.3.3 and in [152]). Here, we conducted a systematic testing of a 
medium sized focused library designed by Veronika F.S. Pape, a former PhD student in 
the lab. The compound library was designed by considering the current understanding of 
the relation between TSCs and MDR-selectivity/cytotoxicity. One of the reference points 
was the β-thiosemicarbazone NSC73306, as this compound (just as its close analogues) 
showed anticancer cytotoxicity, which was potentiated in the presence of functional P-
gp. Arylhydrazones and benzothiazoles have been introduced to the focused library as 
well, as alternatives to thiosemicarbazones (Figure 41), since TSCs exhibit 
pharmacological side effects due to the putative liberation of H2S during their 
metabolism. The rationale behind the chemical library design was to investigate the 
impact of metal chelation to cytotoxicity, particularly to MDR-selective cytotoxicity, as 
the increased proliferation of cancer cells results in an elevated demand for metal ions, 
which creates a vulnerability that can be exploited therapeutically. The size of the library 
was of 50 compounds. 
 
Figure 41. Focused library designed of A) ß-isatin TSCs; B) picolinylidene (i) and salicylidene 
(ii) TSCs; C) picolinylidene (i) and salicylidene (ii) hydrazino-benzothiazoles; D) arylhydrazones 
[153]. 
The compounds of the library were tested against 3 cell line pairs: Mes-Sa & Dx5, KB-
3-1 & KB-V1 and A2780 & A2780adr, using the MTT reagent to determine the viability 
and calculate the IC50 values. I contributed to the cytotoxicity results by testing the growth 
inhibition of the members of this focused library additionally with the fluorescent protein 




and conducted the experiments on 384 well plates as a confirmatory screen. Primary 
screen was missed, as the toxicity of the compounds were already known from the MTT 
measurements. 
To measure the cell mass by the detection of mCherry intensity of the surviving cells was 
necessary, as the compounds, presented in this focused library were considered as so 
called “PAINs” (pan assay interference compounds). PAINs, due to their chemical 
characteristics, interfere with several applied assays resulting in false hits. Chelators, 
present in this library are typically such frequent hitters, e.g. hydroxyl-phenylhydrazone 
compounds have been reported to frequently disturb several diverse in vitro assays [154] 
[155]. Therefore the cytotoxicity had to be confirmed with a counter assay, that works 
based on a different principle than MTT, and the reagent free fluorescent protein based 
assay was a suitable choice.  Comparison of the MTT assay measured on Mes-Sa and 
Dx5 cells to the fluorescent protein based measurement gave a good correlation, 
supporting that the results are not false positives, no observable MTT assay interference 
had occurred (Figure 42). Although the mCherry based assay returned higher IC50 values, 
the two methods provided concordant results. 
A)     B) 
 
Figure 42. Comparison of toxicity of the compounds against Mes-Sa and Dx5 cell lines obtained 
either by MTT reagent or by the fluorescent protein based assay measuring the intensity of 
mCherry. A) IC50 values of the MDR-selective compound NSC73306 (1a; Figure 43). B) 
Correlation of pIC50 values for MTT and mCherry measurements. Pearson correlation was 
calculated to be 0.95 with an r² of 0.87 for Mes-Sa (black) and 0.62 with an r² of 0.91 for Dx5 




In terms of MDR-selectivity, only the NSC73306 like TSCs showed tariquidar sensitive 
hypertoxicity to MDR cells (compounds 1a-e; Figure 43). Collateral sensitivity was 
observed also for some other structures, although this hypertoxicity towards MDR cells 
was unaffected in the presence of P-gp inhibitor tariquidar, suggesting that 
hypersensitivity of the MDR cells cannot be exclusively linked to the activity of P-gp, 
and should be rather explained by off-target effects linked to other specific resistance 
mechanisms or the genetic drift of the selected cells. 
A)     B)      
     
C) 
 
Figure 43. A) General formula of the MDR-selective ß-isatin-TSCs; B) NSC73306 (1a) and its 
analogues; C) GI50 values [μM] of the TSC analogues1a-1e measured against Mes-Sa mCherry 
and Dx5 mCherry cell lines in the absence and presence of tariquidar (TQ). (P < 0.05:*; P < 
0.01:**; unpaired t-test). Panel B was taken from [153]. 
In terms of cytotoxicity (regardless of P-gp overexpression) of the tested chelator 
compounds, the donor atom set proved to be the most determinant factor. The library was 




provides different metal chelating affinities to the compounds. Chelator donor atom set 
determines the binding preference for different metal ions, and stabilizes different 
oxidation states of these ions. The different chelators might influence the redox properties 
of the ions as well. Superior cytotoxic activity of NNS and NNN chelators over ONS 
chelators was observed (Figure 44/B). Regarding to MDR-selectivity, only the ONS-
containing ß-isatin TSCs showed P-gp mediated hypertoxicity, other ONS-containing 
TSCs did not provoke it. It seems, the chelation donor atom set itself is not enough to 
convey the hypertoxicity to P-gp overexpressing MDR cells. 
A)      B) 
 
 
Figure 44. Cytotoxicity of the compounds based on the chelator donor atom set. A) Example 
compounds with ONS, NNS and NNN donor atom set, used in the design of the focused library. 
B) Comparison of overall toxicity data of ONS (red), NNS (blue) and NNN (green) chelators. 
Data from mCherry fluorescence measurements using Mes-Sa and Dx5 cells are shown (**p < 
0.01; figures taken from [153]). 
4.3.4. Screening and testing a medium sized compound library with flavonoids and 
thiosemicarbazones. 
In collaboration with the group of Ahcène Boumendjel (Univ. Grenoble Alpes, 
Département de Pharmacochimie Moléculaire, Grenoble, France), we screened a set of 




flavonoid derivatives and thiosemicarbazones (Figure 45). The rationale behind this 
choice was the fact that flavonoid derivatives have been widely studied as potential 
candidates for cancer treatment and prevention [156] and a number of naturally occurring 
derivatives were reported to be effective against resistant tumors. Although the increased 
cytotoxicity to MDR cells were linked mostly to the MRP1 transporter (ABCC1; 
reviewed in [70]), there are a few examples, where MDR-selective toxicity was dedicated 
to the function of ABCB1. For example the desmosdumotin B flavonoids were reported 
to exhibit significant collateral sensitivity against P-gp expressing vincristine resistant 
cells [84] [85]. However, based on our detailed investigation, we revealed that 
desmosdumotins confer only a marginal effect, which was highly cell line specific (see 
in 4.2.1.2). 
 
Figure 45. Main scaffolds of the 156 membered compound library. 
To filter out not active and less toxic entities, we performed a primary screening. The 
primary screen of the compounds was conducted using the mCherry expressing variants 
of Mes-Sa and Dx5 cell lines on 96 well plates. Growth inhibition (GI) of the compounds 
was determined based on the fluorescence of the mCherry protein expressed by the cells 
reflecting to cell mass, and compounds were sorted based on growth inhibition. The two 
concentrations we used was 10 μM and 100 μM. Of the compounds tested, 13 were toxic 
at a concentration of 10 μM to both cell lines, 32 compounds were not toxic at all even at 





In the next step, we serially diluted each interesting drug in 8 concentrations and 
performed an automated confirmatory screening on 96 well plates to obtain dose-response 
curves. At this step, we intended to demonstrate, that the compounds excert dose-
dependent toxicity, thus IC50 values can be obtained. Therefore we decided to use the 
confirmatory screening only to obtain the right concentration interval, and to approximate 
IC50 values. The confirmatory data then served as an applicable input source for the 
secondary screen where we obtained accurate IC50 values from dose-response curves by 
PrestoBlue viability reagent as a counter assay, where we used non-fluorescent Mes-Sa 
and Dx5 cells. For the secondary experiments, we chose representative compounds from 
all chemotypes, in a way to include the 13 primarily toxic molecules. The result of the 
secondary screen was in concordance with the primary and confirmatory toxicity of the 
compounds: xanthones were the least toxic entities, while chalcones were the most toxic 
ones (Figure 46/A). Moreover, we have found some compounds with selective toxicity 
either to Mes-Sa or to Dx5 cells (Figure 46/B).  
A)        B) 
 
Figure 46. (A) Cytotoxicity of the tested compounds against Dx5 cell lines by the main scaffolds, 
measured by PrestoBlue reagent. (B) Selectivity ratio (SR) of compounds to Dx5 MDR cell line 
compared to Mes-Sa parental cell line (flavones are including the isoflavone genistein). 
The 3-step screening system revealed that scaffolds derived from azaaurones are 
particularly the most promising agents from the aspect of selective toxicity towards the 
MDR cell line Dx5. In 10/13 cases the selectivity ratio (SR) of azaaurones were ≥ 2. We 





















































































































selective toxicity. We tested 4 azaaurones that were more toxic to Dx5 cells (CHB1-59, 
CHB1-43, CHB1-44, CHB1-41) and one that was more toxic to the Mes-Sa cell line 
(CHB1-63). In the presence of tariquidar the azaaurones, which killed Dx5 cells 
preferably became more toxic against both the parental and the MDR cell lines. Moreover 
these compounds kept their selective behavior, without remarkable change in the SR. In 
contrast, the presence of TQ did not influence the IC50 value of CHB1-63 against Mes-
Sa, while the toxicity to Dx5 was significantly increased, suggesting strongly that this 
compound can be a substrate of ABCB1 (Table 15). The reason of the increment of 
CHB1-59, -43, -44 and -41 cytotoxicity against both cell lines in the presence of TQ is 
unknown, and mediated plausibly due to a yet undiscovered effect of the inhibitor. 
Table 15. IC50 values (in µM) of azaaurone compounds in the presence and absence of 
the P-gp inhibitor tariquidar (TQ; 1 µM). SR stands for selectivity ratio and was 
considered significant if the IC50 values were statistically different (unpaired t-test, P < 
0.05:*; P < 0.01:**). 
Azaaurone Mes-Sa Dx5 SR Mes-Sa(TQ) Dx5(TQ) SR(TQ) 
CHB1-59 17.8 ± 4.1 3.7 ± 0.6 4.8** 3.2 ± 0.7 0.8 ± 0.2 4.0* 
CHB1-43 9.4 ± 1.6 2.5 ± 0.2 3.7** 2.5 ± 0.3 0.6 ± 0.01 3.9* 
CHB1-44 50.2 ± 10.0 18.5 ± 5.6 2.7** 16.9 ± 0.3 4.9 ± 0.4 3.5** 
CHB1-41 17.1 ± 1.7 5.8 ± 1.3 3.0* 4.3 ± 0.4 1.1 ± 0.3 3.7* 
CHB1-63 9.2 ± 2.3 19.5 ± 3.5 0.47* 9.6 ± 1.0 6.7 ± 0.7 1.4 
 
To test the cell line specificity, some of the azaaurones were probed against another in 
vitro cell line based MDR model, where we compared the toxicity of A431 human 
epidermoid carcinoma cells to A431-B1 cell line, which expresses P-gp due to retroviral 
transduction of the human MDR1 gene (Table 16). The selectivity ratio of the azaaurones 
in this system was between 0.5 and 2, meaning that the compounds did not confer 
remarkable collateral selectivity nor resistance related to P-gp. Although we have 
observed a slight MDR-selective effect in the case of CHB1-59, which mean that P-gp 
might contributed to the selective toxicity, and A431-B1 cells showed a 1.5 fold resistance 
to CHB1-63 (a SR of 0.67 refers to1.5 fold resistance), which supports that this compound 




Table 16. IC50 values (in µM) of azaaurone compounds against A431 cell lines. SR stands 
for selectivity ratio (P < 0.05:*; P < 0.01:**). 
Azaaurone A431 A431-B1 SR 
CHB1-59 44.6 ± 6.9 27.0 ± 3.0 1.7** 
CHB1-43 33.4 ± 5.5 45.9 ± 6.4 0.7 
CHB1-44 76.1 ± 18.2 75.9 ± 26.0 1.0 
CHB1-41 65.7 ± 3.3 57.4 ± 2.5 1.1 
CHB1-63 10.3 ± 1.4 15.4 ± 2.2 0.67* 
   
Based on the cytotoxicity tests with A431 and A431-B1 cell lines, and based on the 
experiments conducted in the presence of tariquidar, azaaurone compounds did not 
possess general P-gp mediated MDR-selectivity. We observed a marginal P-gp 
potentiated cytotoxic effect in the case of CHB1-59, and identified a P-gp substrate 
(CHB1-63) (Figure 47). 
     
CHB1-41 CHB1-43 CHB1-44 CHB1-59 CHB1-63 
Figure 47. Structure of selected azaaurone compounds, which were investigated in more details. 
From the tested focused compound library, azaaurones were the most potent candidates, 
they showed hypertoxicity (up to 6-fold) against the doxorubicin selected, P-gp 
expressing Dx5 cell line. However, the selective effect was not influenced by the 
inhibition of P-gp, hence azaaurones were not targeting cells with functional P-gp in 
general, and can overcome MDR because of other cellular alterations, which seem to be 
cell line specific. Eventually, the borderline MDR-selective cytotoxicity of CHB1-59 
might worth to be investigated in the future by synthesizing additional analogues. 
The other flavonoid (and TSC) compounds in the library, which killed Dx5 cells 
preferably (Figure 46/B) were also tested in the presence of TQ, but none of them had a 




4.3.5. Investigation of protoflavone compounds against MDR cancer 
In the framework of a cooperation with Attila Hunyadi (SZTE, GYTK, Szeged), we had 
the possibility to investigate another focused library, comprised of the unique flavonoids 
called protoflavones. Protoflavones are rare flavonoids, found mostly in ferns, and some 
members are known from their anticancer properties [157]. Moreover, as Hunyadi and 
colleagues have reported, certain members can evoke a mild collateral sensitivity towards 
P-gp expressing MDR cell lines, which was linked to the decline in oxidative stress 
tolerating capacity of the cell lines that were previously long-term selected with a 
cytotoxic drug [158] [159]. The selective toxicity was suggested to be linked to 
substituents on the C6 position of the protoflavone core, as in the case of an MDR1 
transfected cell line, only compounds with C6-methyl moiety elicited a slight but 
significant collateral sensitivity, and the extent of the effect was only moderately 
influenced by the C1’ substituents (Figure 47). 
Figure 47. Structure of protoflavones with mild selective toxicity (1.31-1.63 fold) against the 
P-gp overexpressing L5178B1 cell lines over the L5178 parental line [159]. Position C6 and C1’ 
are highlighted. The protoflavone skeleton is defined as the compound when C6 harbors a H atom 
instead of the methyl-group, while R=H.  
In the terms of the cooperation we intended to explore the effect of various substituents 
on the cytotoxicity of the protoflavones, particularly to explore the change in 
hypertoxicity to MDR cell lines. Therefore, protoflavones with distinct core structure and 
with various moieties on C6 and C1’-OR were included in the focused library. The library 
enclosed 52 protoflavones in total, of which we tested the cytotoxicity of 26 analogues 






These 26 analogues represent the derivatives of the naturally occurring protoapigenone 
and analogs of the synthetic WYC0209 identified as a potential lead in previous studies 
[160], and a 6-phenyl series of the core protoflavone structure (Figure 48). The compound 
compilation was supplemented with 6-methyl- and 6-pentyl-derivatives of the core 
protoflavone together with the naturally occurring protogenkwanone aiming to further 
explore SAR at C6. 
 
 
Figure 48. Structure of PA-C1’-O-R, 6-phenyl-protoflavon-C1’-O-R and WYC0209-C1’-O-R. 
Protogenkwanone (PG) is the 7-methoxy substituent of PA. 
The assessment of the cytotoxic effect of the protoflavones was initiated with the first 
campaign of primary screening (see in 4.3.1.), where we included the 4 representative 
protoflavone compounds (where R = H based on Figure 48), which we received prior to 
the rest of the analogues.  As these 4 compounds inhibited the growth of both Mes-Sa 
mCh and Dx5 mCh cell lines at 10 μM completely, we compiled a cell line panel, and 
tested a set of 26 analogues manually. The cell line panel we used was comprised of the 
Mes-Sa and Dx5 cell line pair, the KB-3-1 and KB-V1 cell line pair, and the A431 cell 
line with two ABC-transporter transfected variants, the A431-B1 and the A431-G2. Our 
results of the 26 analogues are summarized in Figure 49. 
In general, protoflavones were toxic to every cancer cell line in the panel, and as it was 
expected from the primary screening, a majority of them showed an IC50 value below 
10 μM (thus pIC50 above 5). Several compounds exerted different activity against parental 
and MDR cells, which was quantified based on the fraction of IC50 values obtained in 
P-gp negative vs. positive cells. Accordingly, SR < 0.5 indicated that the compound was 








transporter overexpressing cells demonstrated collateral sensitivity against the tested 
protoflavone derivative. Against the MDR cell line Dx5 only a few compounds showed 
a hypertoxicity approaching or even exceeding the SR of 2. Interestingly, all these 
compounds have an unsubstituted C1’-OH group, while C1’-OR analogues (where R ≠ 
H) were all less effective in killing Dx5 preferably over Mes-Sa. The results for KB-3-1 
and KB-V1 were inconsistent from this aspect, C1’-OH structures were not showing 
higher CS to KB-V1 than the C1’-OR substituted analogues. However, most 
protoflavones provoked collateral sensitivity of the KB-V1 cell line. 
A)      B) 
 
C)        D) 
 
Figure 49. Cytotoxicity of a subset of 26 protoflavone analogues measured by PrestoBlue 
viability assay against (A) Mes-Sa and Dx5, against (B) KB-3-1 and KB-V1 cell lines and against 
(C) A431 parental, A431-B1 and A431-G2 cell lines. (D) IC50 values of protoapigenone and 
mitoxantrone in the absence and presence of ABCG2 inhibitor tariquidar. Dox: doxorubicin; Vbl: 
vinblastine, Mx: mitoxantrone; PA: protoapigenone; TQ: 1 μM tariquidar. SR: selectivity ratio, 
SR > 2 refers to collateral sensitivity, SR < 0.5 refers to drug resistance. P < 0.05:*; P < 0.01:**. 








































































































































When we tested the protoflavones against A431, A431-B1 or A431-G2 cells, we observed 
no collateral sensitivity nor resistance exceeding the 2-fold threshold, except of 
protoapigenone (PA). Resistance of A431-G2 cells to protoapigenone was abolished in 
the presence of tariquidar, confirming that this compound was a subject of the efflux 
transport. Other protoapigenone C1’-OR analogues, especially C1’-O-iPro, seemed to 
have also a slight (but less than 2-fold) substrate manner (Figure 50), thus the affinity of 
protoapigenone derivatives to ABCG2 can be influenced at this position. Interestingly, 
protogenkwanone, which differs from PA only in its 7-methoxy group (Figure 48) was 
not recognized by ABCG2. 
 
 
Figure 50. Selectivity ratio of the various C1’-OR protoapigenone (PA), WYC0209 
(WYC) and 6-phenyl (6Ph) analogues against the cell line pairs. 
As a summary of the systematic experiments with protoflavones, we observed a strong 
cytotoxic activity for most of the derivatives. In terms of the 6-substituents, cytotoxicity 
(and collateral sensitivity) was apparently independent of the moieties attached to C6, as 
the pattern differed from cell line to cell line. All compounds seemed to evade P-gp 
conferred multidrug resistance, which was tested against various in vitro models of 



































































selection in doxorubicin or vinblastine, suffered from a mild to strong degree of collateral 
sensitivity provoked by the protoflavones. However, in contrast to MDR-selective 
compounds, protoflavone derivatives did not target cells engineered to overexpress P-
glycoprotein, suggesting that the increased toxicity observed in the MDR cells is not 
conferred by the efflux pump. Indeed, protoflavones were earlier reported to kill P-gp 
overexpressing cells preferentially due to the altered antioxidative capacity of the cells, 
which was acquired during drug selection [158]. We investigated also the effect of 








The multidrug resistance of tumor cells against chemotherapy mediated by the 
pathological overexpression of P-gp is still an unresolved problem in the clinics. In MDR 
tumors, P-gp is located in the plasma membrane of the malignant cells and protects them 
from the intracellular accumulation of xenobiotics through the active extrusion of a wide 
range of cytostatics or targeted drugs. Attempts in clinical trials to reverse drug 
accumulation of cancer cells by inhibiting the function of P-gp had failed due to 
pharmacokinetic side effects, or simply due to ineffectiveness. A novel approach to fight 
against MDR cancer is based on the phenomenon of collateral sensitivity, when tumor 
resistance is considered as a targetable trait. This phenomenon, known also as fitness cost, 
can be explained with the acquisition of such characteristics, which serve as a drawback 
in a different environment. Several collateral sensitivity provoking compounds were 
reported to kill P-gp overexpressing cancer cells in vitro. Some of them were linked to 
such cellular alterations, which were not influenced by P-gp overexpression. For example, 
in a study of Rickardson et al. [161] the library of pharmacologically active compounds 
(LOPAC1266) was tested against the human myeloma cell line RPMI-8226 and its 
doxorubicin resistant P-gp positive phenotype RPMI-8226/Dox40. Some of the 
compounds, which belong to the cluster of glucocorticoid steroids killed the MDR cells 
preferentially. Subsequent analysis showed that the observed collateral sensitivity was 
linked to the upregulation of the glucocorticoid receptor at the cell surface, which 
facilitated an increased drug accumulation, while P-gp was not contributing to this effect. 
Other compounds, such as austocystin D and 2-deoxyglucose were also reported to kill 
P-gp overexpressing cells preferentially. However, in the case of austocystin D, the 
collateral sensitivity was derived from its selective activation by cytochrome P450 in 
MDR cells [76], while hypertoxicity of 2-DG was linked to the altered apoptotic pathway 
of the investigated MDR lines [74]. If such CS agents are applied and the cell line specific 
changes are targeted during treatment, P-gp overexpression might not be eliminated 
concurrently, thus MDR of the tumor would still be a hurdle of an effective treatment. 
In other instances, collateral sensitivity of P-gp expressing cancer cells was linked to the 
function of P-gp. In some of these reported studies, the causal link between P-gp and 
hypersensitivity of MDR cells to CS agents were not examined thoroughly, thus we 




verapamil, reversin121, TritonX-100, desmosdumotin B flavonoids, rotenone, KP772, 
Dp44mT and the Pluronic block copolymer P85 against a panel of parental & MDR cell 
line pairs in cytotoxicity assays. Unfortunately, except of KP772, none of the compounds 
elicited robust P-gp mediated selectivity in our hands (Tables 8-11; Figure 29). 
Our inability to confirm the reported collateral sensitivity can possibly be explained by 
the fact that both the special cellular changes in the particular cell lines used in the studies 
and the function of P-gp contributed to the observed effect, but P-gp alone was not 
sufficient to confer CS. Another plausible explanation for the irreproducibility of the 
reported data is the difference in the degree of resistance of the applied MDR cell lines. 
While testing desmosdumotin B flavonoids against KB and KB-VIN cell lines, we used 
the same conditions (kanamycin and HEPES supplemented medium) for cell culturing 
and the same assay type (SRB) for cytotoxicity assays to exclude the possibility of any 
assay specific disturbance. Compared to the data in the original article [84], our IC50 
values measured by SRB assay were similar for the parental KB cells, while a remarkable 
difference was seen when we compared the results of KB-VIN. These cells in our hands 
were less sensitive to desmosdumotins, but more sensitive to vincristine (Table 10). The 
IC50 for KB-VIN was 7 μg/ml (which is approx. 8.5 μM) based on the reference [84], 
whereas for us it was only 0.57 μM. As the level of P-gp is proportional to the resistance, 
and inversely related to MDR-selective toxicity [152], unreproducible data might linked 
to the extreme P-gp level of KB-VIN cells used in the original work. Similarly, when we 
examined the cytotoxicity of Dp44mT, we did not observe any lysosomal accumulation 
of P-gp, which might have occurred due to extreme level of transporter overexpression 
(Figure 29). Thus, the in vivo experiments, when KB-3-1 and KB-V1 xenografts were 
treated with Dp44mT in mice  has to be interpreted with caution, particularly because 
xenografts are known for their limited utility, as compared to more realistic tumor models, 
the response of xenografts to drug treatment is more pronounced [162] [163]. When 
Richardson et al. treated the xenografted mice with Dp44mT, a more than 5-fold reduction 
was observed in the growth of the KB-V1 xenografts over KB-3-1 xenografts, albeit the 
KB-3-1 consisting tumor grew faster also when vehicle control was administered [103]. 
As indicated, when treated with KP772, MDR cells were killed by this drug to a greater 
extent as a consequence of functional P-gp expression (which was reproducible also in 




promising and more preferable drug candidates, as the source of their hypertoxicity is 
linked the function of P-gp, which is at the same time the causative factor of MDR to 
chemotherapeutics. KP772 was tested also in vivo against human DLD-1 colon carcinoma 
xenografts in mice [164]. Albeit it had a promising anticancer properties comparable to 
cisplatin and methotrexate treatment, no experiments were reported, when MDR tumors 
were treated. 
Our research group used a systematic approach to identify P-gp potentiated MDR-
selective agents in a previous study, which proved to be highly useful, and led to the 
identification of NSC73306 and other MDR-selective compounds from the NCI DTP 
drug repository [73] [98]. Later, as presented in this thesis, we repeated the consecutive 
in silico filtering and in vitro validation of the MDR-selective candidate drugs, and 
identified 6 compounds, which killed 4 P-gp positive cell lines preferentially over the 
parental counterparts, unless P-gp was inhibited (Tables 12-14). Hypertoxicity against 
MDR lines was observed both when long-term drug selected cell lines and when MDR1 
transfected cells were used. The best performing hit compound we identified was the 
8-OH-Q analogue NSC297366, which was tested against additional cell line pairs, where 
we further demonstrated its robust effect. As apparent from Figure 51, NSC297366 
provoked MDR-selectivity in every case, which was abrogated in the presence of the P-gp 
inhibitor TQ, regardless also of the cytotoxicity assay type we used. 
Besides the 8-OH-Qs (especially NSC297366 and NSC57969), other structural congeners 
were also associated with MDR-selectivity. Of the compounds we identified in the 
repeated datamining from the DTP repository, we have found two 1,10-phenanthroline 
complexes (same chemotype as KP772), a diketone compound (NSC17551) and a 
compound which is a sulfonated 7,8-dihydroxy-quinoline condensed to a 1,4-
naphtoquinone (NSC13977). We also identified a thiosemicarbazone compound 
NSC716771, which is a close analogue of NSC73306, although we were not able to 
purchase it and verify its MDR-selective cytotoxicity in our hands. 
Despite the dissimilarity of the 2D structures of the identified MDR-selective chemotypes 
(Figure 30), an earlier drug activity pattern analysis by our research group revealed an 
association with metal chelation complexes [98], suggesting that metal binding is relevant 




compounds and their structural congeners could chelate metal ions [98] [165] [166] [167], 
or were present already in a metal-bound form. The metal chelating coherency seemed to 
be valid also for the MDR-selective compounds we identified from the new release of the 
DTP repository, e.g. ß-diketones (chemotype of NSC17551) were already used as 











Figure 51. Robustness of the MDR-selective cytotoxicity of NSC297366. OVCAR-8 and NCI-
ADR/RES cells were measured with the fluorescent protein based assay (based on DsRed2 and 
eGFP, respectively); KB cell lines were tested with SRB assay; other cell lines were tested with 
PrestoBlue viability reagent. Statistics: unpaired t-test, P < 0.05:*; P < 0.01:**. TQ: 1 μM 
tariquidar. 
Based on the experiments with the 8-OH-Q core structure, which is a strong metal 
chelating agents, but cannot provoke P-gp mediated MDR-selectivity to any cell lines 
[151], we assume that metal ion coordination is necessary but not sufficient for the effect 
of MDR-selective compounds. However, details of the mechanism of action of selective 
toxicity remains elusive. As reviewed partly by our research group [70], it is possible that 
P-gp simply increases the intracellular accumulation of an MDR-selective compound. 
Alternatively, by extruding a physiological substrate, P-gp can unshield the molecular 
target of an MDR-selective compound. It is also possible, that the function of P-gp is 














































































































Finally, an MDR-selective compound might bind an intracellular component, and the 
complex that was formed is already recognized and effluxed by P-gp, resulting in the 
depletion of the ligand (putative mechanism are shown in Figure 52). The most common 
species believed to be depleted by P-gp, either directly or conveyed by the transporter, 
are ATP, GSH or metal ions. 
 
Figure 52. Putative mechanism of action of an MDR selective compound. (I) accumulation of 
MDR-selective compound (red star); (II) unshielding of molecular target (yellow square); (III) 
activation of MDR-selective compound linked to the efflux of compound ’X’; (IV) depletion of 
endogenous substrate (green circle) [70]. 
MDR-selective compounds, besides the preferable killing of P-gp positive MDR cells 
possess a second unique feature: when P-gp expressing, drug resistant cancer cell lines 
were treated with non-toxic concentration of an MDR-selective compound, P-gp 
disappeared from the cell surface due to the decrease in the mRNA level transcribed from 
MDR1 [152]. Moreover, the MDR-selective substances identified from the systematic 
DTP repository data mining (including KP772) induced the loss of P-gp already in 
response to one single, 5 day long, high dose treatment [151]. This so called P-gp 
phenotype switch seemed to be permanent, as the P-gp expression did not return after the 
MDR-selective agent was removed. In contrast, example compounds (e.g. verapamil) 
eliciting cell line specific collateral sensitivity and the non-selective 8-OH-Q core 




The aim of the research on MDR-selective compounds is to utilize them in future cancer 
treatment. There are several possibilities, how therapeutic modalities can benefit by the 
application of such molecules. If P-gp is already present and confers resistance to the 
tumor, MDR-selective compounds can be administered (alone or in combination with a 
chemotherapeutic agent) either to selectively eliminate the transporter expressing cells, 
or to downregulate the expression of P-gp, thus re-sensitizing the tumor to the applied 
chemotherapeutic agent. Alternatively, MDR-selective compounds can also be used to 
prevent the occurrence of MDR phenotype by administering them simultaneously, 
consecutively or prior to cytostatic or chemotherapeutical treatment. Unfortunately, there 
are no MDR-targeting therapies to date, because crucial in vivo proof-of-concept studies 
are still missing. 
Therefore, we decided to perform a compound screening followed by preliminary lead 
optimization to find more potent MDR-selective agents, which could be used efficiently 
in in vivo experiments. 
To have the capacity of testing a large amount of molecules, we established an automated, 
high throughput amenable screening platform. Cytotoxicity testing was designed in 3 
consecutive screening steps, which provided more detailed information of the tested drugs 
in every step. The results of the 3 steps (I-III) indicated if compounds are cytotoxic (I, 
primary), gave confirmed dose-dependent response, preferably in an MDR-selective 
manner (II, confirmatory), and if the MDR-selectivity was robust across different parental 
& MDR models and across assay procedure types (III, secondary) (Figure 7). 
The growth inhibition in the primary and confirmatory screens was measured by a 
fluorescent protein based cytotoxicity assay. This novel type of reagent free assay was 
based on the detection of fluorescent protein expression, as the fluorescent intensity was 
proportional to the cell number. We adapted and developed this type of assay based on 
publications, where fluorescent proteins were utilized in cytotoxicity measurements. The 
fluorescent protein based cytotoxicity assay was automated and was compatible with both 
96 well and 384 well microplates. During the implementation of the assay, the special 2D 
growth characteristics of Mes-Sa mCherry and Dx5 mCherry cell lines was to be 
considered (Figures 19, 20, 25). Due to visible evaporation from the side wells by 144 h, 




commonly encountered systemic error appearing because of physical or environmental 
variances of the wells within a plate [138], and the affected area of the plates were 
excluded from the cytotoxicity experiments (Figure 26/C). Moreover, the measurements 
were continuously checked for their reliability via calculating the Z’-factor of each 
microplate (Tables 3, 5, 6, 7; Figures 16, 24, 28), which reported on assay robustness. 
The fluorescent protein based assay was selected for screening purposes because the 
reagent free detection of cell viability grants cost effectiveness in long term, and because 
it is free of liquid handling, which is highly advantageous in automated processes, as 
pipetting is always a possible source of error. Moreover, as the detection of the fluorescent 
signal is not harmful to the cells (“quasi label free”), fluorescent intensity of wells can be 
measured even every day, thus following cell growth is also achievable if needed. 
The primary compound screening was performed in campaigns to minimize the 
disturbing effect of external factors. Based on primary growth inhibition results, we 
excluded mostly only the non-toxic hits to narrow the number of compounds, which lead 
to a high hit ratio compared to the HTS performed by pharmaceutical companies, where 
hit ratio is ideally around 2%. However, our high hit ratio was designed on purpose, as 
we intended to use the cytotoxicity data of as many agents as possible, to perform detailed 
SAR studies on toxicity and on MDR-selectivity. Moreover, compound purchase was 
already designed in a way to include such compounds that were tailored to be inactive to 
prove the importance of certain structural elements that are absent or blocked in the 
modified molecules, thus non-toxicity was also a source of information. 
In between the primary campaigns, the interesting molecules were tested in the 
confirmatory and secondary steps. The testing was based on designed focused libraries of 
chemotypes. The focused libraries we tested, and which were introduced in the frame of 
this thesis were (i) 8-hydroxy-quinolines, (ii) TSCs and analogues, (iii) TSCs and 
flavonoids including azaaurones and (iv) protoflavones. 
The library of 8-hydroxyquinolines investigated herein was compiled based on a previous 
intellectual property search, and the results of the new chemical entities (NCE) were filed 
in as an international patent application “MDR-reversing 8-hydroxy-quinoline 
derivatives”. The optimization of the 8-OH-Qs returned 2 potent subtypes, where R2 was 




group, and R7 was constituted either from methoxy-benzylamines or tetrahydro-
isoquinoline derivatives (Figures 36, 40; structures represented in Figure 52). The non-
cell line-specific MDR-selective potency of the NCEs was quantified by the normalized 
activity index (NAI), which was calculated from both the selectivity ratio (SR) and the 
cytotoxicity of a compound. The best performing hit NSC297366 that we identified from 
the DTP repository possessed a NAI of negative values (-0.54, -0.02, -0.36 against A431 
& A431-B1, Mes-Sa & Dx5 and MDCK II & MDCK II B1, respectively), while the best 
performing NCEs returned a NAI of 4.70, 3.76 and 4.05 for the same cell lines. (NAI is 
the interpretation, of the optimization, where NAI = 0 is the average improvement, while 
positive values show compounds with ‘better than average’ MDR-selective effect). In 
vivo experiments with the optimized 8-OH-Qs are already under elaboration, preliminary 
results are expected in the near future. 
 
 
Figure 52. General formula of the 8-hydroxyquinoline derivatives, which were the subject of the 
patent application “MDR-reversing 8-hydroxy-quinoline derivatives”, and the structure of the 
most potent compounds as a result of optimization. 
Although thiosemicarbazones (TSCs) are known for their potential MDR-targeting 
properties [73][100][101], when a focused library of TSCs, hydrazino-benzothiazoles and 
aryl-hydrazones were tested, we unfortunately did not identified more potent compounds 
in terms of MDR-selectivity. However some of the compounds shown relatively high 
level of collateral sensitivity against Dx5 cells, but this preferential effect was not linked 
to the function of P-gp. Nevertheless, with the study [153], we provided new insights of 
the relation of cytotoxicity and metal chelation, which was particularly important, as 
chelators are often considered as pan assay interference compound (PAINSs), and it was 
also a task for us to demonstrate the cytotoxicity of such compounds with a reagent free 
assay, as MTT (or PrestoBlue) might react with redox active metal complexes. 




cytotoxicity of chelators are discussed in publications, as automated algorithms of the 
scientific journals recognize PAIN-like structures, and the submitted manuscript will be 
rejected without any substantive review. To exemplify that the identified MDR-selective 
agents are not false positive results due to the redox cycling of non-toxic compounds, we 
probed a set of 80 compounds, including e.g. 8-OH-Qs, TSCs, ß-diketones and 
arylhydrazones, and we compared the GI50 data measured against Mes-Sa mCh and Dx5 
mCh after 144 h incubation (confirmatory screen was performed on 384 well plates) to 
the IC50 values obtained from PrestoBlue viability measurements at 72 h (against non-





Figure 53. Correlation of fluorescent protein based detection of growth inhibition and PrestoBlue 
viability measurement against (A) Mes-Sa mCherry and Mes-Sa cell lines, and (B) against Dx5 
mCherry and against Dx5 cell lines. 
The correlation (Figure 53/A and B) demonstrated that fluorescent protein based 
measurement data was in concordance with the conventional PrestoBlue viability 
measurement, thus the PAIN issue did not interfere with our results. Not shown here, but 
we demonstrated the MDR-selective cytotoxicity of NSC57969 also by measuring 
apoptosis with Annexin V and propidium-iodide staining [151]. 
We probed also several flavonoids to test their putative MDR-selectivity. As seen, 
desmosdumotin B analogues worked cell line specifically. Similarly, distinct subtypes of 
protoflavones (protoapigenone, WYC0209 and 6-phenyl-protoflavone analogues) 














































influenced by the presence of P-gp (Figures 49 and 50). This behavior was further evinced 
by Hunyadi and colleagues, when they tested the 26 analogues as a part of a 52 membered 
protoflavone compound library against 2 additional cell line pairs (L5178 and L5178B1, 
and MCF-7 and MCF-7Dox, Figure 54/A and 54/B, respectively) [169].  
A)      B) 
 
Figure 54. Cytotoxicity (pIC50) of 52 protoflavone analogues measured by MTT against (A) 
L5178 and L5178B1 and against (B) MCF-7 and MCF-7Dox cell lines, performed by Attila Hunyadi 
and colleagues. Dox: doxorubicin; SR: selectivity ratio, SR > 2 refers to collateral sensitivity, SR 
< 0.5 refers to drug resistance. P < 0.05:*; P < 0.01:**. 
The tested analogues, of which some returned an IC50 value below 1 μM against L5178 
or A431 cell line variants, were equally toxic to L5178 and MDR1 transfected L5178B1 
cell lines (SRs were below 2), indicating, that the compounds can overcome MDR, 
although the contribution of P-gp in this phenomenon is not remarkable. On the contrary, 
many compounds showed hypertoxicity to MCF-7dox cells compared to the parental 
MCF-7, with SR values exceeding 5 in the case of 12 compounds. Thus, tested 
protoflavones were not MDR-selective compounds, although their potent cytotoxicity, 
even if ABCB1 or ABCG2 transporters are present, can be exploited in an anticancer 
therapy, as P-gp mediated multidrug resistance was overcome. 
When we tested the flavonoid library containing 3-aryl-2-quinolones, flavones, aurones, 
azaaurones, chalcones, xanthones and azaflavones, the most relevant hits were the 
aurones, especially azaaurones. These compounds seemed to be even more interesting 
candidates, as an in silico hit from the DTP repository, NSC43320 belongs also to 
aurones, and it was eliciting collateral sensitivity against KB-V1 cells over KB-3-1 [98]. 













































several analogues. To explore, if the preferential toxicity was conveyed by functional P-
gp, we repeated the experiments with co-incubating tariquidar and selected azaaurones. 
Surprisingly, non-toxic concentration of TQ exerted an increase in azaaurone 
cytotoxicity, while the SRs remained significant (Table 15). Thus, we probed the selected 
analogues also against A431 and MDR1 transfected A431-B1, and we demonstrated the 
slight (1.7-fold), but significant MDR-selective cytotoxicity of the analogue CHB1-59 
(Table 16). 
The compound compilation, which we purchased and already tested in the primary 
screening (Figure 35) contains the congeners of more chemotypes than presented in this 
thesis. However, the additional chemotypes are still under continuous in vitro 
investigations in confirmatory and secondary screening steps, and a few manuscripts will 
probably be submitted in the near future. 
Our screening results were characterized also from a statistical point of view by 
monitoring assay robustness via the Z’-factor. As the fluorescent protein based 
cytotoxicity assay is not used commonly in the literature, we could compare our Z’-
factors only to fluorescent protein measurements based on different principles, introduced 
in point 1.4.4. In the study of Rao et al., the high content screening was performed on 384 
well plates with Z’-factors of 0.50 and 0.54 for eGFP and mCherry, respectively [131]. 
In the study of Kenny et al., where a fluorescent laser scanning microplate cytometer was 
applied, the Z’-factors varied between 0.4–0.7 on 384 and 1536 well formats (Figure 55, 
[133]). In comparison, our Z’-factors were generally better for mCherry, eGFP and 
mOrange fluorescent proteins (Tables 5, 6, 7; Figures 16, 24, 28), reaching the maximal 
average value of 0.87 in the case of Dx5 eGFP measurement on 384 well plates after 144h 
incubation time. 
 






1. I established and characterized a fluorescent protein based cytotoxicity assay, and 
proved that it is amenable to screen putative MDR-selective substances in a higher 
throughput. 
2. I found that reported compounds do not possess robust MDR-selective activity, 
and the provoked collateral sensitivity was linked to other factors than functional P-gp. 
3. I extended the systematic datamining of the NCI DTP drug repository. This 
analysis has led to the identification of robust MDR-selective compounds. 
4. I performed structural clustering of the known MDR-selective compounds in order 
to associate 2D structures (chemotypes) to the observed effect. 
5. By screening the cytotoxicity of 2160 compounds, which were purchased based 
on the chemotypes that were associated with MDR-selective cytotoxicity, I facilitated the 
generation of lead (or lead like) compounds. 
6. I contributed to the understanding of essential structure-activity relationship of 8-
hydroxy-quinolines, which led to the development of more, highly active compounds. 
The most potent, so far unknown analogues were the basis of the international patent 
application “MDR-reversing 8-hydroxy-quinoline derivatives”. 
7. I investigated the MDR-selective cytotoxicity of structural congeners of 









Due to inherent or acquired therapy resistance, cancer remains a deadly disease. One of 
the cellular factors contributing to the simultaneous resistance of tumors to multiple 
treatments is associated to the overexpression of ABC transporters (multidrug resistance, 
MDR). P-glycoprotein (ABCB1/P-gp) confers MDR to cancer cells by keeping the 
concentration of cytotoxic agents below a cell-killing threshold. Whereas transporter 
inhibition did not achieve clinical success, MDR-selective compounds preferentially 
targeting P-gp expressing cancer cells represent a new and promising approach for the 
resolution of cancer MDR.  
The overall aim of my doctoral work was to establish a screening platform for the 
identification of more potent MDR-selective analogs. I found that compounds reported in 
the literature to possess MDR-selective toxicity were in fact not robustly toxic to a panel 
of MDR cell lines, suggesting that their activity is limited to specific cellular alterations 
not related to P-glycoprotein. In contrast, our analysis of the NCI60 database identified 
several MDR-selective compounds, whose toxicity is potentiated, rather than attenuated 
by P-gp, irrespectively of the particular cell model. In silico and in vitro characterization 
of these compounds lead to the identification of highly active molecules, clustering into 
distinct chemotypes associated with MDR-selectivity. Focused libraries built around the 
molecular scaffolds were obtained, and their toxicity was characterized in a dedicated 
screening platform. Therefore, I established an automated screening system amenable to 
high-throughput based on a reagent free cytotoxicity assay measuring the growth 
inhibition of fluorescent protein expressing cell lines. 
In the primary screening campaign I tested the cytotoxicity of 2160 compounds against a 
parental and an MDR cell line. 4 focused compound libraries were then assayed in 
consecutive confirmatory and/or secondary screening tests, characterizing dose-
dependent cytotoxicity, cell line specificity and the contribution of P-gp to cytotoxicity. 
Testing and limited optimization of the 8-hydroxy-quinoline scaffold resulted in analogs 
with significantly increased toxicity and MDR-selectivity, leading to an international 
patent application. By testing thiosemicarbazones, protoflavones and flavonoids, we 
observed crucial relationships between structure and activity, which were reported in 2 





A malignus tumorok eredményes kezelésének egyik fő korlátja a kezelés során 
rendszerint kialakuló multidrog rezisztencia (MDR), ami sokszor az ABC-transzporterek 
fokozott sejtfelszíni expressziójához köthető. A P-glikoprotein (ABCB1/P-gp) efflux 
funkciójának köszönhetően megvédheti a rákos sejteket az alkalmazott kemoterápiás 
szerektől. Az MDR leküzdésére fejlesztett transzporter gátlók klinikailag hatástalannak 
bizonyultak, azonban az ún. MDR-szelektív vegyületek alkalmazásával lehetőség nyílt 
egy újszerű, kifejezetten az MDR tumorokat célzó kemoterápia fejlesztésére, mivel 
bizonyos vegyületek a P-glikoprotein funkciójának függvényében hatékonyabban 
képesek elpusztítani az MDR tumorsejteket. 
A doktori munkám során a jelenleg ismert MDR-szelektív vegyületeknél hatékonyabb 
analógok azonosítása céljából kialakítottam egy molekulaszűrési eljárást. A 
szakirodalomban publikált, P-glikoproteint kifejező sejtvonalakat szelektíven támadó 
vegyületek tesztelésekor azt tapasztaltam, hogy a megnövekedett toxicitás a transzporter 
funkciójától függetlenül, sejtvonal specifikusan jelentkezett. Ezzel ellentétben, a 
kutatócsoportunk szisztematikus in silico és in vitro megközelítéssel az NCI60 
adatbázisából sikeresen azonosított számos olyan molekulát, melyek citotoxicitását 
kifejezetten fokozta a P-gp funkciója. A validált MDR-szelektív vegyületeket szerkezetük 
alapján kemotípusokba soroltuk, és fókuszált vegyület-könyvtárakat állítottunk össze, 
hogy minél hatásosabb vezérmolekula jelölteket találhassunk. A molekulák szűrésérét 
egy nagy áteresztőképességű rendszeren keresztül valósítottam meg, melyhez bevezettem 
egy reagensmentes, fluoreszcens fehérje expresszión alapuló citotoxicitási esszét.   
Az elsődleges szűrés során 2160 vegyület toxikusságát teszteltem le egy parentális és egy 
MDR sejtvonalon. Ezt követően a megerősítő és másodlagos tesztek során 4 fókuszált 
vegyületkönyvtárat teszteltük le, hogy meggyőződjünk a dózis-függő szelektív 
toxicitások sejtvonal specifikusságáról és P-gp függéséről. A 8-hidroxi-kinolinok 
tesztelésének és limitált optimalizációjának eredményeként olyan analógokat találtunk, 
amelyek toxikussága és MDR-szelektivitása szignifikáns mértékben megnövekedett, így 
egy nemzetközi szabadalmi beadványt nyújtottunk be. A tioszemikarbazonok, 
protoflavonok és flavonoidok tesztelésének eredményeként alapvető szerkezet-hatás 
összefüggéseket figyeltünk meg, melyeket 2 tudományos közleményben publikáltunk, 
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Appendix 2. Example plate maps for testing cytotoxicity on 384 well plates. 
 
Locations of the 36 molecules on the 384 well plate during primary screening. Cells were 
seeded prior to drug pipetting. Light green: 10 μM, dark green: 100 μM concentrations of 
the tested drugs; grey: positive control (0% viability), blue: negative control (100% 
viability). 
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Locations of the 9 dilution points of the 8 compounds on the 384 well plate in a secondary 
screening plate map. Cells were seeded prior to drug pipetting. Compounds 1-4 and 5-8 
were normalized to the adjacent negative controls (3 parallels each). Darker green refers 
to higher test compound concentrations (marked only for compound 1); grey: positive 
control, blue: negative control. 
Appendix 3. Automatic data evaluation vs. evaluation of individual measurement by the 
GraphPad Prism software. 
Comparison of the pGI50 values that were obtained by both techniques, we subtracted the 
one calculated automatically by our custom program from the other that was determined 
via Prism. The differences were in general low, especially for Dx5 cell line. The observed 
differences can partly emerge from the elimination of outlier data points, which is a built-
in function in the Prism software, and was used during data evaluation, and partly due to 
‘problematic’ dose-response data, where the sigmoidal shape was defective. 
 
The differences of pGI50 values of 80 compounds calculated by subtracting the 
automatically evaluated data from manual pGI50 determination with the GraphPad Prism 
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software. The cytotoxicity was obtained from a confirmatory screening with 144 h 
incubation time against Mes-Sa mCherry (orange) and Dx5 mCherry (blue) cell lines. 
The red lines refer to 2-fold difference in GI50 (which is approx. ± 0.3 in pGI50). 
Appendix 4. Identification of fluorescent compounds by measuring the plates set for 




Fluorescent intensity of the wells, measured right after compounds were added to the cells 
(0 h measurement). The volume of the culture medium and the amount of the cells were 
equal in every well, thus outlying fluorescent intensities can be addressed only to 















































compounds, which are fluorescent by nature. 0 h measurements shown in panel A were 
acquired in the mCherry channel, while panel B shows compound fluorescence in the 
eGFP channel to have a broader overlook, and to utilize the results, when experiments 
with eGFP expressing cell lines are planned. On panel A, the upper limit of the fluorescent 
intensity on the X-axis was set to 5000, to visualize the lower RFU values, although the 
intensity of the most fluorescent compound was above 80 000 units. 
Appendix 5. Automated seeding is not harmful to the cell lines. 
 
Mes-Sa cells were attached to the bottom of the well 24 h post seeding, and no floating 
cells were observed. The confluency of the wells were identical after 72 h incubation. 
Appendix 6. Pearson’s coefficients for the in silico hits. 
Compound Pearson's coeff.  Compound Pearson's coeff. 
NSC1014 0.433  NSC608465 0.441 
NSC13977 0.481  NSC609800 0.401 
NSC15372 0.421  NSC627452 0.405 
NSC17551 0.481  NSC672035 0.409 
NSC48892 0.500  NSC676735 0.452 
NSC57969 0.684  NSC726708 0.405 
NSC67090 0.416  NSC733435 0.407 
NSC72881 0.407  NSC740469 0.507 
NSC79544 0.717  NSC748494 0.538 
NSC297366 0.461    
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